EP1056843A1 - Blocage therapeutique de la synthese de icer pour prevenir l'inhibition a mediation icer de l'activite de cellules immunitaires - Google Patents

Blocage therapeutique de la synthese de icer pour prevenir l'inhibition a mediation icer de l'activite de cellules immunitaires

Info

Publication number
EP1056843A1
EP1056843A1 EP99903134A EP99903134A EP1056843A1 EP 1056843 A1 EP1056843 A1 EP 1056843A1 EP 99903134 A EP99903134 A EP 99903134A EP 99903134 A EP99903134 A EP 99903134A EP 1056843 A1 EP1056843 A1 EP 1056843A1
Authority
EP
European Patent Office
Prior art keywords
icer
cells
expression
nfat
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99903134A
Other languages
German (de)
English (en)
Inventor
Peter A. Cohen
Josef Bodor
David E. Weng
Gary K. Koski
Brian J. Czerniecki
Jana Bodorova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of EP1056843A1 publication Critical patent/EP1056843A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • cancer cells may induce the production of prostaglandin E2 (PGE2) in neighboring normal host cells such as macrophages.
  • PGE2 prostaglandin E2
  • PGE2 inhibits the prolifieration of T cells, thereby reducing the ability of the host immune system to destroy the cancer cells.
  • Tumor cells and infectious agents may also produce other substances which directly or indirectly reduce the activity of the host's immune response. Accordingly, there is a need for therapeutic strategies which prevent or reduce downregulation of the host immune response.
  • the present invention relates to strategies for preventing or reducing downregulation of the immune response in individuals suffering from afflictions in which downregulation of the immune response contributes to the progress of the disease.
  • afflictions include cancer or infection with a pathogen.
  • the agent comprises a nucleic acid.
  • the nucleic acid comprises a ribozyme capable of cleaving at least one site in at least one isoform of
  • the nucleic acid comprises an antisense nucleic acid comprising a sequence complementary to at least a portion of at least one isoform of ICER mRNA.
  • Another aspect of the present invention is the use of an agent which decreases the level of ICER expression in the preparation of a medicament for increasing the activity of an immune cell.
  • the agent comprises a nucleic acid.
  • the nucleic acid comprises a ribozyme capable of cleaving at least one site in at least one isoform of ICER mRNA. In other embodiments, the nucleic acid comprises an antisense nucleic acid comprising a sequence complementary to at least a portion of at least one isoform of ICER mRNA.
  • the medicament is for the treatment of cancer. In other embodiments, the medicament is for the treatment of infection with a pathogenic organism, in some embodiments, the immune cell is selected from the group consisting of T cells, B cells, NK cells, monocytes, dendritic cells and antigen presenting cells. In other embodiments, the immune cell is a T cell. 2
  • Another aspect of the present invention is a ribozyme comprising at least one catalytic sequence having endonuclease activity and at least one targetting sequence, wherein the at least one targetting sequence is complementary to a sequence present in at least one isoform of ICER mRNA.
  • the agent comprises a nucleic acid.
  • the nucleic acid comprises a ribozyme comprising at least one catalytic sequence having endonuclease activity and at least one targetting sequence, wherein the at least one targetting sequence is complementary to a sequence present in at least one isoform of ICER mRNA therein.
  • the nucleic acid comprises an antisense nucleic acid comprising a sequence complementary to at least a portion of at least one isoform of ICER mRNA.
  • the immune cell is selected from the group consisting of T cells, B cells, NK cells, monocytes, dendritic cells and antigen presenting cells.
  • the immune cell is a T cell.
  • Another aspect of the present invention is a method for increasing the activity of an immune cell comprising decreasing the level of ICER expression in said immune cell.
  • the level of ICER expression is decreased by introducing a nucleic acid which inhibits ICER expression into the immune cell.
  • the nucleic acid comprises a ribozyme capable of cleaving at least one site in at least one isoform of ICER mRNA.
  • the nucleic acid comprises an antisense nucleic acid comprising a sequence complementary to at least a portion of at least one isoform of ICER mRNA.
  • the immune cell is selected from the group consisting of T cells, B cells, NK cells, monocytes, dendritic cells and antigen presenting cells.
  • Another aspect of the present invention is a method of increasing the activity of immune cells in an individual comprising the steps of removing immune cells from the individual, introducing an agent which inhibits ICER expression into the immune cells, and reintroducing the immune cells into the individual.
  • the agent comprises a nucleic acid.
  • the nucleic acid comprises a ribozyme capable of cleaving at least one site in at least one isoform of ICER mRNA.
  • the nucleic acid comprises an antisense nucleic acid comprising a sequence complementary to at least a portion of at least one isoform of ICER mRNA.
  • the immune cell is selected from the group consisting of T cells, B cells, NK cells, and antigen presenting cells. In further embodiments, the immune cell is a T cell. In some embodiments, the individual suffers from a condition which reduces immune cell activity. In other embodiments, the individual is infected with a pathogenic organism. In other embodiments, the individual suffers from cancer. Another embodiment of the present invention is a method of increasing the activity of immune cells in an individual comprising introducing an agent which inhibits ICER expression into immune cells in the individual. In some embodiments, the agent comprises a nucleic acid.
  • the nucleic acid comprises a ribozyme capable of cleaving at least one site in at least one isoform of ICER mRNA.
  • the nucleic acid comprises an antisense nucleic acid comprising a sequence complementary to at least a portion of at least one isoform of ICER mRNA.
  • the immune cell is selected from the group consisting of T cells, B cells, NK cells, and antigen presenting cells.
  • the immune cell is a T cell.
  • the individual suffers from a condition which reduces immune cell activity.
  • the individual is infected with a pathogenic organism
  • the individual suffers form cancer.
  • Fig. 1 provides the nucleotide sequence of the ICER gene (SEQ ID NO. 1)
  • Fig. 2 illustrates the structures of the four ICER transcript isoforms.
  • Fig. 3 illustrates the ICER expression pattern in T cells treated with lonomycin, forskolin, or lonomy cm + forskolin.
  • Fig 4 illustrates the ICER expression pattern in monocytes treated with forskolin, prednisolone, IL- 10- GM CSF, and lonomycin.
  • Fig. 5 illustrates the inhibitory effects of forskolin treatment on the proliferation of T cells contacted with a variety of agents which normally induce proliferation.
  • Fig. 6 illustrates the ICER expression pattern in monocytes whose lonophore-induced differentiation is inhibited by forskolin.
  • RIBOQUANT probes hCKJ (A) and hCK3 (B) in the RNase protection assay are also shown. Also shown are the corresponding RNase protected robes following hybridization with yeast tRNA in the presence (+) (lane 7) or absence ( ⁇ ) (lane 8) of RNase.
  • RNA levels (Pharmingen). Note that each probe (lane 8) migrates slower than its protected band; this is due to flanking sequences in the probe that are not protected by mRNA.
  • C Western immunoblotting using ICER-specific antiserum generated against a peptide encompassing the ICER-specific exon (36) shows induction of ICER in medullary thymocytes after 3hrs, but not after 12 hrs of forskolin treatment. There is no ICER protein detectable before treatment or in forskolin-treated human cortical thymocytes which corresponds to a lack of detectable ICER mRNA reported previously in cortical thymocytes (36). Fig. 8.
  • NFAT/AP-1 composite sites of IL-2 promoter delineated previously to be essential for IL-2 expression (63) used in EMSA analysis.
  • NFAT and AP 1 top denote domains of homology between NFAT/ AP-1 composite sites and consensus sequences for NFAT and AP-1 in human IL-2 promoter, respectively. Numbers on the left correspond to the relative distance of the depicted DNA-binding motifs from TATA box of the IL-2 promoter.
  • ICER Bacte ⁇ ally expressed ICER binds in boiled total bacterial lysate specifically to (-90) (lanes 3 and 4) and (-160) CD28RE 4 motifs (lanes 7 and 8) and to a limited extent also to the rest of the motifs.
  • the binding of ICER to these motifs is specific since it is recognized by CS4 CREM-specific antiserum (CS4) causing a specific supershift (sICER) while the nonspecific complex (NS) remains unperturbed both in the presence of CS4 ( + ) and normal rabbit antisera (-).
  • the control CRE consists of an oligonucleotide encompassing 21 bp repeat of HTLV-I LTR (H21 CRE) (64).
  • C In vitro binding of purified recombinant ICER and NFAT DBD (NFAT) proteins yields NFAT/ICER ternary complex (NF/IC) on
  • CD28RE motif (460) (lane 12) and to lower extent also on NFAT -45 motif (lane 3).
  • D ICER and truncated Fos and Jun proteins (AP) form similar complexes (NF /IC versus NF / AP) in the presence of NFAT DBD (NFAT) on the (-160) motif of the IL-2 promoter (lanes 3 and 9), which are recognized by the CS4 anti-CREM (C) (lane 4) and DX anti-Fos (D) (lane 10) or K25 anti-Jun (K) (lane 1 1) and to a limited extent also by R59 NFAT (R) antisera (lane 12), respectively.
  • Both unlabeled oligonucleotides NFAT (nf) (lane 6 and 13) and AP-1 (ap) (lanes 7 and 14) efficiently compete for complex.
  • ICER protein can interact directly with NFAT DBD. Decreasing amounts of NFAT DBD protein retained on Sepharose matrix with equal amounts of GST-linked ICER (GST-ICER, lanes 1 , 3, 6) alongside with a negative control represented by equivalent amounts of GST matrix alone (GST, lanes 2, 4, 7) interact specifically in GST-pull down assay. Lane 5 represents the input of NFAT DBD which is equivalent to protein added to GST-ICER beads retained in GST-pull down in lane 3. In contrast, GST-CREB (lane 10) does not interact with comparable amounts of NFAT DBD protein (input, lane 8). Lane 9 represents GST-CREB beads alone.
  • NFAT DBD retained on GST-ICER Sepharose beads was separated by SDS-PAGE and visualized by Western blotting using the NFAT-specific antibody R59.
  • Fig. 10 ICER binds to a conserved proximal element of the IFN ⁇ promoter homologous to the (-90) motif of
  • ICER binds to both human and mouse motifs of the IFN ⁇ promoter (lanes 2 and 9), despite that these motifs fail to bind NFAT DBD (NFAT) (lanes 3 and 10 4 a fashion analogous to the (-90) motif of the IL-2 promoter.
  • NFAT NFAT DBD
  • ICER bound to the proximal element of the IFN ⁇ promoter is specifically "supershifted" (sICER) by a CS4 CREM-specific antibody (C) (lanes 5 and 12).
  • ICER forms complexes on several NFAT/AP-1 composite sites in GM-CSF, IL-4, and TNF-a promoters.
  • C-E NFAT/AP-1 composite sites in GM-CSF, IL-4 and TNF- ⁇ promoters bind to ICER and form ICER containing complexes in whole ceil extracts prepared from freshly prepared 5 human medullary thymocytes.
  • ICER and ICER containing complexes were competed by unlabeled oligonucleotides containing CRE motifs (ere) (lanes 4, 7, 10) or NFAT motifs (nf) (lanes 5, 8, 1 1) (panels C and D) and were immunoreactive with
  • ICER isoform II represses transcription from NFAT/AP-1 activated cytokine promoters stimulated by PMA and ionomycin (P + l) treatment.
  • IL-2-CAT human interleukin-2 (61 ) CD28RE (-160 AP- Luc); GM-CSF-CAT (54) (human granulocyte-macrophage colony stimulating factor), TNF- ⁇ -Luc (contains the sequence from -614 to +20 of the human tumor necrosis factor-a in pGL2).
  • a control (3xGAL4)-CR-CAT (with three GAL-4 binding sites substituting 21-bp repeats in the HTLV-1 LTR, (64)) and transactivated by GAL4VP16 (73) is not affected in Jurkat cells by isoforms of ICER (ICER II, ICER lly, ICER 1).
  • B Amounts of respective cytokine reporters and ICER expression constructs in transient transfectiom were kept constant (2 ⁇ g). Error bars represent standard deviations calculated from three or more experiments.
  • Peripheral blood T lymphocytes can induce stable ICER protein upon forskolin (F) or PGE 2 (P) treatment.
  • Immunoprecipitations of total 35 S labeled cell lysates using CREM-specific antiserum (C) and normal rabbit serum (N) show accumulation of ICER protein in peripheral blood T lymphocytes after 3, 12, and 18 hrs of forskolin (0.1 mM final) (F3, F12, F18) or PGE 2 (500ng/ml final) treatment (P3, P12, P18).
  • ICER protein is barely detectable in untreated (U) negatively selected T cells (lanes 1 and 2) while clearly detectable 3hrs after the both treatments (lanes
  • Fig. 14 Forskoiin-mediated transcriptional attenuation of cytokine and chemokine expression in IL- 12 induced Th1 - and IL-4 induced Th2-like human peripheral blood T lymphocytes correlates with induction of potent transcriptional repressor ICER.
  • In vitro polarized T cell populations with Thi or Th2 dominant phenotypes were evaluated by flow cytometry analysis (A). Shown are T lymphocytes (containing more than 95% of CD3 * cells) which were typically obtained after in vitro priming and polarization toward the Th1 or Th2 dominant phenotypes.
  • the non- CD3 * cells were CD14 + (1 % in Thi and less than 1 % in Th2), CD19 * (1 % in Thi and 2% in Th2) and CD16 * (2% in Thi and 5 % in Th2).
  • PBMC primed as described were maintained in the medium containing IL-2 until the restimulation.
  • the cells were cultured for a total of two weeks prior to restimulation, Th1 and Th2 populations shifted significantly towards the memory phenotype, represented by the CD45R0 marker.
  • the Thi population 57% of CD4 * cells and 35% of CD8 * cells maintained the same ratio of CD4 * versus CD8 * after polarization as prior to polarization (data not shown).
  • the Th2 dominant culture contained 60% of CD4' and 14% of CD8 * cells.
  • RNAs from IL-12 induced Th1 and IL-4 inducedTh2 dominant populations were restimulated with PHA either in the absence (•) or presence of forskolin ( + ) and scored in parallel for human cytokine (B) and chemokine 6 expression (D) in parallel with ICER mRNA(C and E) using the RNase protection assay.
  • hCK1 probes For evaluation of expression of human cytokines (B) a Riboquant set of hCK1 probes (hlL-5, hlL-4, hlL-10, hlL-14, hlL-15, hlL-9, hlL-2, hlL-13, and hlFN- ⁇ ) was used while for evalution of expression of human chemokines (D) was used Riboquant set of hCK5 probes
  • Fig. 15 Differential susceptibility of cytokine expression in Th1 and Th2 dominant subsets to cAMP- mediated inhibition after restimulation with either phorbol ester plus ionophore (P+ l) or ph ⁇ tohemaglutinin (PHA).
  • P+ l phorbol ester plus ionophore
  • PHA ph ⁇ tohemaglutinin
  • RNAs were scored in the RNase protection assay for cytokine and ICER expression using human cytokine Riboquant set of hCK1 probes (hlL-5, hlL-4, hlL-10, hlL-14, hlL-15, hlL-9, hlL-2, hlL-13, and hlFN- ) (PharMingen) and JL5 probe (74) respectively.
  • RNA levels (PharMingen, San Diego, CA). Note that each probe (lane 14) migrates slower than its protected band; this is due to flanking sequences in the probe that are not protected by mRNA.
  • Fig. 16 ICER-mediated transcriptional attenuation of cytokine and chemokine expression in activated lymphocytes from ICER transgenic mice.
  • ICER transgenic ( + ) or control nontransgenic (-) thymocytes were activated with PMA + ionomycin for three hours.
  • RNAs were isolated and analyzed in the RNase protection assay in parallel for cytokine (A) or chemokine production (B) as well as ICER expression (data not shown) using Riboquant sets for mCK1 probes (mlL-4, mlL-5, mlL-10, mlL-13, mlL-15, mlL-9, mlL-2, mlL-6, m INF- ⁇ ,) or mCK5 probes (mLtn, mRANTES, mEotaxin, mMI ⁇ , mMIP-1 ⁇ , mMIP-2, mlP-10, mMCP-1, mTCA-3) (Pharmingen), respectively.
  • each probe migrates slower than its protected band; this is due to flanking sequences in the probe that are not protected by mRNA.
  • Fig. 17 A proliferative defect in lymphocytes from ICER transgenic mice.
  • A Freshly isolated thymocytes from ICER transgenic or control nontransgenic littermates were isolated, and total 35 S-labeled cell lysates were assayed by immunoprecipitation using a CREM specific antiserum (c) along with control normal rabbit serum (n).
  • Proliferation of splenocytes B) activated for 48 hrs with ConA, PMA plus ionomycin (PMA + ionophore) or by immobilized anti-CD3 monoclonal antibody (2C11 ) was measured by 3 H-thymidine incorporation.
  • C Allogeneic 7 response in mixed lymphocyte reaction of C57BL/6 splenocytes from ICER transgenic or nontransgenic control mice to allogeneic BALB/c splenocytes. Irradiated, unfractionated splenocytes from syngeneic C57BL/6 or allogeneic BALB/c splenocytes were added to cultures containing unfractionated ICER transgenic or nontransgenic C57BL/6 splenocytes After 48 hours of coincubation thymidine uptake was measured as described.
  • D Cell yields from thymus and spleen of transgenic and nontransgenic animals.
  • ICER proteins are induced early in response to forskolin in freshly isolated human peripheral blood CD3 + T lymphocytes but only to limited extent in CD19 * B lymphocytes.
  • Immunoprecipitations using CREM specific antiserum (C) (116) and normal rabbit antiserum (N) show induction of ICER proteins (17-20 kDa) in unseparated lymphocytes after three hours of forskolin (F) treatment (0.1 mM final) (lanes 1 to 4).
  • ICER proteins are detectable in untreated (U), positively selected, CD3 * T cells (lanes 5 to 8) showing higher background levels in comparison with positively selected CD19 * B cells (lanes 13 to 16) and/or their respective pass throughs (CD3 + PT, CD19 + PT) (lanes 9 to 12, and 17 to 20, respectively). Purity of freshly isolated CD3 * T cells and CD19 * B cells was evaluated by subsequent flow cytometry analysis. Background levels of ICER proteins are specific since control immunoprecipitations of untreated Jurkat T cells (lanes 21 and 22) do not yield any detectable ICER protein in agreement with lack of detectable ICER mRNA (see Fig. 22B, lane 1 ) while after forskolin treatment both ICER mRNA
  • FasL expression as assessed by RNase protection used for evaluation of mRNA of multiple constituents of Fas and TNF pathways in 2B4 T cells (FLICE, FasL, Fas, FADD, FAP, FAF, Fas2L, TNFRp55, TRADD, and RIP) was dramatically altered after the treatments (B).
  • Activated phorbol ester-io ⁇ omycin treated 2B4 T cells induce ICER in the presence of forskolin after three hrs (P+l + F) (lane 6) to similar or even higher levels than after forskolin treatment alone (F) (lane 18).
  • FasL down-regulation correlates with increased ICER expression in activated human peripheral blood T lymphocytes after forskolin treatment.
  • Purity of negatively selected human peripheral blood T cells was evaluated by flow cytometry analysis. RNAs from freshly prepared human peripheral blood T lymphocytes were treated for three hours with phorbol ester and ionomycin (P+ l) either in the presence of forskolin (F) or absence of forskolin (U) and scored in parallel for FasL or ICER mRNAs using RNase protection assay with hAP03 RIBOQUANT or ICER probes, respectively.
  • Activated human peripheral blood T cells after phorbol ester and ionomycin treatment show decreased levels of FasL message in the presence of forskolin (P+l/F) (top, lane 1 ) accompanied by increased levels of ICER (middle, lane 1 ).
  • T cells activated by phorbol ester and ionomycin expressed higher levels of FasL message (A, lane 2) accompanied by lower levels of ICER mRNA (middle, lane 2).
  • FasL message A, lane 2
  • ICER mRNA middle, lane 2
  • Templates for the analysis of hL32 and hGAPDH housekeeping genes were included to allow assessment of total RNA levels (PharMingen).
  • Fig. 21 Induction of FasL expression in phorbol ester activated human peripheral blood NK lymphocytes is accompanied by cessation of ICER expression.
  • Elutriated peripheral blood lymphocytes were used to isolate CD56 * NK cell population (Miltenyi Biotec, Auburn, CA). Purity of CD56 * NK cell population was evaluated by flow cytometry analysis (see Experimental Procedures). RNAs from either untreated (U), and one (P1) or three hours (P3) of phorbol ester treated cells were scored using RIBOQUANT probe hAP03 (PharMingen, San Diego, CA) (A) or ICER (B).
  • hFAP and hTRADD elevated levels of mRNAs for hFAP and hTRADD and the corresponding RNase-protected hAP03 probes following hybridization with yeast tRNA in the presence ( + ) (lane 3) or absence (-) (lane 4) of RNase.
  • Templates for the analysis of hL32 and hGAPDH housekeeping genes were included to allow assessments of total RNA levels. Note that each probe (lanes 1 and 2) migrates slower than its protected band (lane 4); this is due to flanking sequences in the probe that are not protected by mRNA.
  • Fig. 22 Elevated levels of ICER can be detected in human peripheral blood CD56 * NK cells as well as in human NK cell lines NK3.3 and NK92 prior to forskolin treatment.
  • A Immunoprecipitations using CREM-specific antiserum (C) or normal rabbit antiserum (N) show presence of ICER protein in untreated CD56 * NK cells (U) (lane 2) with moderate increase after three hours of forskolin (F) treatment (lane 4). ICER protein is detectable in untreated CD56 + NK cells prior to forskolin treatment.
  • B RNAs from human NK cell lines NK 92 and NK 3.3 were scored in
  • Fig. 23 ICER binding and formation of an NFAT/ICER complex with proximal NFAT motif of the FasL promoter.
  • A Listed NFAT motifs of FasL promoter delineated previously to be essential for NFAT-driven FasL expression in T lymphocytes (171 , 172) were used in electromobility shift assay analysis along with control NFAT/AP- 1 composite sites in IL-2 and GM-CSF promoters which can bind ICER directly as well as indirectly (166).
  • NFAT and AP-1 denote domains of homology between NFAT/AP-1 sites and consensus sequences for NFAT in human Fas ligand, and NFAT and AP-1 sites in IL-2, and GM-CSF promoters, respectively. Numbers on the left correspond to the relative distance of the depicted DNA-binding motifs from the transcription initiation site.
  • B Purified, bacterially expressed ICER binds specifically to proximal NFAT motif of Fas ligand promoter (lanes 1 and 2) and to a limited extent also to the distal NFAT motif (lanes 3 and 4).
  • the control NFAT/AP-1 composite sites consists of oligonucleotides encompassing (-160) position of human IL-2 promoter (lanes 7 to 9) and (-420) position of human GM- CSF promoter (lanes 10 to 12) which bind ICER directly and/or yield NFAT/ICER ternary complex (NF/IC) (166). Free, stands for free probe.
  • Fig. 24 ICER represses transcription from luciferase reporter of human FasL promoter activated by anti- CD3 ⁇ antibody (clone 2C1 1 ) in 2B4 T cell hybridoma; hFasL (-225) Luc reporter contains proximal NFAT binding site (from -144 to -126); hFasL (-511 ) Luc reporter contains both proximal (from -144 to -126) and distal (from -283 to - 263) NFAT sites (panel A).
  • IFN- ⁇ interferon- ⁇
  • MIP-1 ⁇ macrophage inflammatory protein-1 ⁇
  • MIP-1 ⁇ macrophage inflammatory protein-1 ⁇
  • 8-Br-cAMP 8-Br-adenosine X, 5' • cyclic monophosphate AICD, activation induced cell death;
  • AP-1 Activating protein 1 bZIP, basic region/leucine zipper;
  • BZTP Basic region/leucine Zipper 10 cAMP, 3', 5' - cyclic adenosine monophosphate
  • CD28RE CD28 responsive element
  • CRE cAMP response element
  • CREB CRE binding protein
  • EMSA Electromobility shift assay FasL, Fas ligand, GM-CSF, granuloc ⁇ te-monocyte colony stimulating factor
  • GM-CSF Granulocyte-monocyte colony stimulating factor
  • HTLV-I Human T cell leukemia virus
  • ICER Inducible cAMP early repressor
  • IFN ⁇ Interferon- ⁇ IL-12, interleukin-12
  • IL-2 lnterleukin-2
  • IL-4 lnterleukin-4
  • NFAT DBD DNA binding domain of NFAT NFAT: Nuclear factor of activated T cells
  • PGE 2 prostaglandin E 2 PKA: Protein kinase A
  • TcR T cell receptor
  • the 1 1 present invention relates to the therapeutic use of antisense nucleic acids to downregulate the activity of the Inducible cAMP Early Repressor (ICER) protein, a protein involved in repressing immune cell activity.
  • ICR Inducible cAMP Early Repressor
  • CRE-BP CRE-binding proteins
  • CREM-t One subgroup of these factors, typified by CREB proteins but also individual CREM proteins such as CREM-t, possess glutamine-rich "Q domains" flanking the P box which mediate nuclear transcriptional activation after the P box is phosphor ⁇ lated.
  • P box phosphorylation is accomplished by several enzymes, including the cAMP-activated enzyme Protein Kinase A (PKA). Therefore, this "Q domain"-containing subgroup of CRE-BP includes constituitively expressed nuclear transcription activating factors which can be switched on by cAMP-induced phosphorylation.
  • PKA Protein Kinase A
  • CRE-BP a subgroup of CRE-BP, typified by constituitively expressed CREM proteins such as CREM- , CREM- and CREM- , lack the activating gluamine-rich "Q" domains, and therefore function as nuclear transcription repressor factors; phosphorylation of their P-box via cAMP/PKA diminishes their activity. While cAMP elevation can lead to phosphorylation but not de novo synthesis of the above two subgroups of
  • CRE-BP a third subgroup, the family of ICER isoforms, was discovered in contrast to be inducible by cellular cAMP elevation. Because all ICER isoforms lack a P-box, phosphorylation is unlikely to play as prominent a role in its function as in the P-box containing CRE-BP. In addition, because all ICER isoforms lack "Q" domains, they function as nuclear repressors. (Lalli, E. and P. Sassone-Corsi, 1994. "Signal transduction and gene regulation: the nuclear response to cAMP" J of Biol Chem 269: 17359-17362, the disclosure of which is incorporated herein by reference).
  • ICER mRNA is transcribed from an internal promoter located in an intron within the CREM gene.
  • the ICER promoter contains four CREs in tandem and is highly inducible by cAMP in a variety of neuroendocri ⁇ e cell lines, including AtT20 corticotrophs, GH3 and GC somatotrophs/lactotrophs, -TSH thyrotrophs, -T3 gonadotrophs, PC 12 pheochromocytoma cells, and JEG-3 choriocarcinoma cells.
  • ICER I isoforms of the ICER transcript, designated as ICER I, ICER I , ICER II, and ICER II , each of which encode proteins having a DNA binding domain.
  • each isoform of translated ICER protein includes a bZIP DNA binding domain (DBD I or DBD II), ICER l/ICER I , isoforms containing DBD I and ICER ll/ICER II , isoforms containing DBD II.
  • DBD I or DBD II bZIP DNA binding domain
  • ICER l/ICER I isoforms containing DBD I
  • ICER ll/ICER II isoforms containing DBD II.
  • the bZIP domain is present in a number of proteins which regulate transcription. Proteins containing bZIP domains are capable of forming heterodimers with other bZIP proteins which have unique DNA binding and transcriptional characteristics.
  • ICER is believed to heterodimerize with and block the activating properties of other nuclear transcriptional activators such as CREB. As described in more detail below, ICER can form ternary inhibitory complexes with the nuclear factor of activated T cell (NF-AT).
  • the ICER protein binds to CREs in the ICER promoter, thereby enabling autorepression of the ICER gene.
  • ICER has also been shown to influence a variety of corticotroph functions. Unregulated ectopic expression of ICER produced drastic effects on corticotroph morphology. Forskolin treated cells expressing high levels of ICER are blocked in the G2/M phase of the cell cycle through downregulation of the cyclin A promoter mediated by ICER binding to CREs therein. (Lamas, M. et al., Molecular Endocrinology 11 : 1425-1434,
  • ICER antisense in these cells overcomes the G2/M block.
  • the present invention is based on the observation that, in addition to its activity in neuroendocrine cells such as corticotrophs, ICER may be involved in downregulating the activity of a wide variety of genes involved in stimulating the immune response.
  • ICER binds to a number of recognition sites present in the promoters of genes encoding cytokines critical to the immune response. Accordingly, procedures for reducing the level of ICER expression in immune cells are useful both as therapeutic treatments to prevent downregulation of immune cell activity and for studying the mechanisms of regulation of immune cell activity.
  • reduction in ICER expression levels may be used to modulate immune cell activity by bloaking repression of cytokine expression and/or other functions of cells of the immune system.
  • ICER expression was upregulated in medullary thymocytes or T cell lines treated with either forskolin or PGE2, both of which are known agonists of the cAMP signalling pathway.
  • forskolin or PGE2 both of which are known agonists of the cAMP signalling pathway.
  • ICER mRNA levels were elevated in T cells treated with both forskolin and the protein synthesis inhibitor cycloheximide relative to the mRNA levels observed in cells receiving forskolin alone, indicating that ICER may autorepress its promoter in T cells as well as in neuroendocrine cells.
  • ICER Expression in T Cells can be Induced by Agents other than cAMP
  • T cell receptor T cell receptor
  • Cl calcium ionophore
  • pharmacologic 13 agents Protein Kinase C activators like PMA/TPA
  • crosslinking of the T cell's CD28 molecule with anti-CD28 antibody or the addition of antigen-presenting cells which express appropriate costimulatory molecules (2,3).
  • T cell proliferation and cytokine secretion can be inhibited by a variety of agents, including cAMP agonists, IL-10 and glucocorticoids (2,3).
  • cAMP agonists including IL-10 and glucocorticoids (2,3).
  • ICER mRNA induction in the presence of Cl or the cAMP agonist forskolin was investigated.
  • ICER mRNA induction in the presence of Cl or the cAMP agonist forskolin was examined as follows.
  • Lymphocytes were obtained by leukapheresis/elutriation from normal human donors (4), and CD4 + T cells were isolated using commercially-available negative immunoselection columns (4). These CD4 * T cells were cocultured every two weeks with autologous monocytes which were pulsed for 24 hours with tetanus protein (TET) prior to coculture (4). rlL-2 (300 lU/ml) was added every 3-4 days to the coculture to promote outgrowth of TET- specific CD4 + T cells. At the end of a growth cycle, the CD4 + T cells were washed and rested in IL-2-free medium overnight.
  • TET tetanus protein
  • ICER I induction appears prominent for both forskolin and ionomycin, whereas other isoforms are prominently induced only in the presence of ionomycin. After 30 hours of culture, ICER induction is prominently sustained only in the group treated with both forskolin and ionomycin. ICER expression in monocytes was investigated as described in Example 2 below.
  • Calcium ionophore (Cl) induces dendritic cell (DC)-like differentiation of monocytes, including de novo expression of the costimulatory molecule B7.1 (4), U.S. Patent No. 5,643,786 (issued July 1 , 1997), and U.S. Patent Application Serial No. 08/885,671 filed June 30, 1997, the disclosures of which are incorporated herein by reference.
  • cytokines such as GM-CSF (6).
  • certain other agents inhibit Cl-mediated differentiation of monocytes and DC, including cAMP agonists such as PGE2 and forskolin, interleukin-10, and glucocorticoids (6-1 1).
  • cAMP agonists such as PGE2 and forskolin
  • interleukin-10 interleukin-10
  • glucocorticoids 6-1 .
  • Each of these inhibitory agents suppresses the induction of B7.1 expression seen in 14 monocytes with Cl treatment (6).
  • the ability of each of these agents-either "inhibitory” or “stimulatory"-- to induce ICER mRNA in monocytes was studied.
  • Monocytes were obtained by leukapheresis/elutriation from normal human donors (4). They were freshly cultured in several groups: No treatment, forskolin (100 micromoiar), prednisolone (10 micromoiar), rlL-10 (1000 units/ml), GM-CSF (50 ng/ml), calcium ionophore (ionomycin 1 microgm/ml). After four hours of culture, the groups were harvested and an RNAase protection assay for ICER mRNA was performed as described in (5).
  • RNAase protection assay for ICER mRNA was performed as described in (5) Predicted bands for ICER isoforms are identified at the right. Additionally occurring bands are believed to be artifacts resulting from polymorphisms where the samples' ICER sequence differs from the assay's ICER template (derived from the T cell leukemia Jurkat (5)).
  • ICER induction is apparent in all treated groups (calcium ionophore > > IL-10 > forskolin > prednisolone > GM-CSF).
  • ICER I induction is the most apparent induced isoform, although all isoforms are prominently induced with calcium ionophore.
  • Example 3 Sustained ICER Expression cAMP agonists (forskolin, PGE2, dibutryl cAMP) have been used by others to induce ICER expression in a variety of cells. In such experiments, ICER mRNA expression was transient, generally abating after several hours.
  • ICER protein binds to and inhibits its own promoter, thereby turning off ICER mRNA transcription (12).
  • ICER protein itself appears to have a half life of several hours and undergoes rapid proteosomal degradation after undergoing ubiquination (13). Because of these observed metabolic tendencies, it would not be predicted that sustained ICER mRNA would be observed, since the presence of ICER protein would be expected to downregulate mRNA synthesis by repressing the ICER promoter.
  • Anti-TET CD4 * T cells were freshly prepared and expanded in culture as described above. After resting in IL- 2-free medium overnight, the cells cultured with nothing, forskolin (100 micromoiar), ionomycin (1 microgm/ml), or ionomycin plus forskolin were collected for ICER mRNA determinations (see above) at 4 hours and at 30 hours of culture.
  • microproiiferation assays were performed as follows. After resting in IL-2-free medium overnight, the anti-TETANUS human CD4 * T cells were stimulated with nothing, ionomycin (1 microgram/ml), 50 u/ml 15 rhlL-2, TETANUS-pulsed autologous monocytes, or immobilized anti-CD3 (100 ng/well). Each treatment condition was tested with or without forskolin (100 micromoiar). Tritiated thymidine ( 3 H-TdR) was added at 24 hours and the cells harvested at 40 hours to determine proliferation The cells were counted by a scintillation counter to determination cell proliferation during that period.
  • 3 H-TdR Tritiated thymidine
  • ICER mRNA determinations 100 micromoiar, calcium ionophore (ionomycin 1 microgm/ml), or forskolin plus ionophore either in 24 well plates for subsequent FACS analysis or in 6 well plates for ICER mRNA determinations.
  • cells were harvested and an RNAase protection assay was performed as described in Bodor et al (5).
  • Cells were collected for ICER mRNA determinations (see above) at 4 hours and at 30 hours of culture. At 30 hours cells were also harvested from the 24 well plates for determination of their expression of the costimulatory molecule B7.1.
  • ICER induction is prominently sustained only in the group treated with both forskolin and ionophore.
  • ICER I and ICER II appear to be the two most prominent isoforms at 30 hours ( Figure 6).
  • sustained high levels of ICER mRNA expression were also observed. Although it is conceivable that such sustained ICER mRNA expression may be occurring in the absence of high levels of ICER protein, it is likely that in this case high levels of ICER mRNA expression are accompanied by high levels of ICER protein translation. Without being limited to a particular mechanism of action, it appears that such sustained ICER expression requires simultaneous stimulation through more than one signalling pathway: for example, both an inhibitory (cAMP agonist) and a stimulatory (calcium ionophore) signal may be necessay. Thus, as described below, therapeutic strategies which reduce or prevent sustained expression of ICER may be particularly efficacious.
  • ICER is also induced in NK cells.
  • Example 5 ICER Induction in NK Cells Inducing cAMP in cultured NK lymphocytes inhibits NK target directed lysis (14). This suggests that ICER is inducible in NK cells and may inhibit various NK functions. ICER induction in NK cells was evaluated as follows.
  • lymphocytes were leukapheresed and elutriated to observe a lymphocyte rich fraction (4).
  • the lymphocytes were cultured with anti CD56 coupled immunoparamagnetic beads, washed, then applied to a magetized column to positively select for NK cells, which were subsequently eluted off the magnet (4). This resulted in NK cell purification to 95-98%.
  • NK cell purification was tested for ICER mRNA and protein expression at various time points (time 0, 24 hrs), with or without forskolin treatment to induce cAMP.
  • NK cells Positively immunoselected NK cells initially expressed ICER; in other experiments, it was found that NK cells purified instead by negative immunoselection did not express ICER, indicating that positive immunoselection itself induced ICER. However, such expression was transient. Within 24 hours in culture ICER levels had returned to baseline, but ICER expression could then be reinduced with forskolin treatment (not shown).
  • ICER expression is also inducible in B cells, as described in Example 6 below.
  • ICER expression is inducible by forskolin in X-50 7 and AKATA cell lines, which are transformed B cell lines (5).
  • treating lymphocytes with both the cAMP agonist PGE2 and immune complexes results in prolonged B cell unresponsiveness, whereas either treatment alone does not (15,16);
  • B lymphocytes were freshly prepared to > 95% purity from fresh human peripheral blood lymphocytes using positive selection with ant ⁇ -CD20 coupled immunoparamagnetic beads (see above). Insufficient numbers were 18 obtained for culture, but the freshly isolated B cells expressed ICER protein, similarly to NK cells freshly isolated by positive immunoselection (see above).
  • Example 8 The above results indicate that ICER expression occurs in normal B cells as well as transformed B cell lines, and may account for the putative inhibitory effect of cAMP agonists in several circumstances.
  • ICER sustained expression of ICER protein occurs under conditions which cause sustained expression of ICER mRNA, the procedure of Example 8 is performed.
  • ICER mRNA Conditions which cause Sustained Expression of ICER mRNA
  • Cells are exposed to combined stimuli which induce sustained expression of ICER mRNA and which cause strong functional inhibition, such as forskolin plus ionomycin.
  • Protein samples are obtained from the cells and levels of ICER protein are determined using an antibody which recognizes the ICER protein.
  • ICER protein levels in cells in which which sustained expression of ICER has been induced are compared to those of uninduced cells. The results indicate that ICER sustained expression of ICER protein occurs under conditions which induce sustained expression of ICER mRNA.
  • cAMP signaling is inhibitory to T cell proliferation and effector functions.
  • cAMP inhibits the expression of T helper- 1 cytokine genes (30-32).
  • T helper- 1 cytokine genes (30-32).
  • fibroblasts showed that elevated levels of intracellular cAMP inhibit upstream signal transduction pathways involved in cell growth and differentiation (33, 34).
  • T cell ERK1 and ERK2 are insensitive to elevated levels of intracellular cAMP (35).
  • cAMP-mediated inhibition of JNK kinase in T cells shows delayed kinetics, an observation that correlates with the induction of the cAMP-inducible early repressor ICER (36).
  • overexpression of NFAT achieved by transfection of NFAT-encoding cDNAs to lymphoma cells abrogates the sensitivity of cAMP-mediated inhibition of IL-2 gene expression (37,38).
  • ICER is a transcriptional repressor that appears to serve as a generalized negative regulator of the CREB and CREM family of transcription factors as well as other related bZIP family members (41-44).
  • ICER isoforms represent a unique cAMP-inducible CREM subfamily of transcription factors containing cAMP response elements within an internal P2 promoter. Because of autoregulation of the cAMP-inducible P2 promoter, the expression of ICER can be intrinsically rhythmical. The rhythmical expression of ICER was first described in the pineal 19 gland and in the hypothalamic-pituitary-gonadal axis (45,46).
  • the P2 promoter of ICER is also inducible in organs other than the pineal and hypothalamic-pituitary gonadal axis such as in specific subsets of T lymphocytes including human medullary thymocytes (36).
  • T lymphocytes including human medullary thymocytes (36).
  • ectopically expressed ICER can substitute for the inhibitory effects of cAMP on the transcriptional attenuation of IL-2 promoter activity (36).
  • the Nuclear Factor that Activates T cells (NFAT) and Activating Protein 1 (AP-1 ) represent two major transcription factor families implicated in the transcription of the IL-2 promoter in proliferating T lymphocytes (47-49).
  • NFAT/AP-1 composite sites that reside within the IL-4, GM-CSF, and TNF- ⁇ promoters resemble those located within the IL-2 promoter (52-56). It is believed that the mechanism underlying the actions of NFAT requires the binding of NFAT and/or NFAT/AP-1 to the NFAT/AP-1 composite binding motifs as ternary complexes (47). These complexes are believed to be essential for the transcriptional expression of immunoregulator ⁇ cytokines during T cell proliferation, such as IL-2, IL-4, GM-CSF, and TNF- ⁇ (48).
  • ICER binds to these NFAT/AP-1 composite DNA sites in vitro, either directly or indirectly via complex formation with the rel homology region of NFAT (NFAT DBD). Furthermore, induction of ICER-immunore active complexes was detected in extracts prepared from human medullary thymocytes treated with forskolin and ionomycin. Ectopically expressed ICER represses transcription from the IL-2, GM-CSF, and TNF- ⁇ promoters activated by ionomycin and phorbol ester, suggesting that the induction of ICER in response to cAMP may be responsible for the observed cAMP-mediated transcriptional attenuation of T helper- 1 cytokine responses.
  • Thymocytes Human thymus glands were obtained from children (ages 3 months to 4 years) undergoing corrective carliac surgery. Thymocytes were fractionated over discontinuous Percoll gradients (Pharmacia) (57). Cells with densities of 1.060 ⁇ o ⁇ 1.070 and P > 1.070 were collected and classified into large (significantly enriched for medullary thymocytes) and small (cortical) thymocytes according to an established protocol (36). Separated human thymocytes were maintained in short-term cultures in RPM1 1640 medium, supplemented with 10% fetal calf serum, 50 units/ ml penicillin, and 25 ⁇ g/ml streptomycin, and treated as indicated. RNase Protection Analysis
  • RNA extraction was performed as described (Qiagen).
  • RNA probes hCK1 and hCK3 were purchased from Pharmingen and labeled with [ ⁇ - 2 P]CTP using reagents from an RNA probe kit (Ambion). These probes were used for RNase protection studies according to the protocol provided by Ambion (RPAII Ribonuclease Protection Assay kit). 20
  • CS4 horseradish peroxidase conjugated to a secondary antibody (Amersham) diluted 1:5,000 for 1 h, followed by nine washes and finally developed using an ECL kit (Amersham).
  • Human IC ER II cDNA was subcloned into the pGEXKG vector (Pharmacia) and expressed in bacteria as a GST- fusion protein.
  • the pGSTagCREB construct was described previously (58). Purifications of both ICER and CREB were carried out with minor modifications according to the protocol previously established for CREB (58).
  • NFATpXS(1 -187) encompassing the minimal DNA-biding domain of NFATp was expressed in bacteria as a hexahistidine-tagged protein and purified as reported previously (59).
  • Binding reactions were performed in a 15 ⁇ l reaction volume containing 20 mM HEPES, 1mM MgCI2,50 mM KCl, 12% glycerol, 0.1 mM EDTA, 0.5 mM DTT, 0.2 ⁇ g poly (dl-dC) as an unspecific competitor, and recombinant proteins or whole cells extracts as indicated.
  • 32P-labeled oligonucleotides and, where indicated, unlabeled competitor oligonucleotides in excess were added and incubated for 10 min at room temperature. Samples were run on a 4% polyacrylamide gel in 0.5 x TBE at 200 V for 2 h following 2 h pre-run at 4 degrees C. The dried gels were exposed for autoradiography overnight.
  • the oligonucleotides encompassing NFAT composite sites of the following human promoters were used:
  • SEQ ID NO.2 IL-2 (-45) 5'-ctagaCATTTTGACACCCCCATAATATTTTTCCAGAATTa-3'; SEQ ID NO.3: IL-2 (-90) 5'-ctagaGTCTTTGAAAATATGTGTAATATGTAAAACATa-3'; SEQ ID NO.4: IL-2 (-135) 5'-ctagaATCAGAAGAGGAAAAATGAAGGTAATGTTTTa-3'; SEQ ID N0.5: IL-2 (-160) 5'-ctagaAAAGAATTCCAAAGAGTCATCAGAAa-3'; SEQ ID NO.6: IL-2 (-280) 5'-ctagaAAGAAAGGAGGAAAAACTGTTTCATACAGa-3'; SEQ ID NO.7: GMCSF(-330) 5'-gatccCCCCATCGGAGCCCCTGAGTCAGCATGGa-3'; SEQ ID NO.8: GM-CSF (-420) 5-gatccCATCTTTCTCATGG
  • SEQ ID NO.11 CTCATa-3'; TNF- ⁇ (-95) 5'-gatccTTCCTCCAGATGAGCTCATGGGTTTCTCCACGACGGAa-3'.
  • IL-4 TNF- ⁇
  • oligonucleotides were used: nf (mouse IL4 NFAT, positions -69 to -79) SEQ ID NO. 12: 5'-ATAAAATTTTCCAATGTAAA-3'; ap (human metallothionein HA AM site [MREI, positions -1 14 to -88)
  • SEQ ID NO. 13 5'-GAGCCGCAAGTG ACTCAGCGCGGGGCG-3', and ere (mouse c-fos gene oligonucleotide, surrounding
  • GST pulldown assays GST-ICER (GST-CREB) sepharose beads prepared as described above were diluted 1:10 in 50 mM Tris pH7.5,150 mM NaCl, 0.5 mM EDTA, 10 mM Na3 (P04)2, 10 mM NaF, 0.1 % Triton X100, 2.5 mM Leupeptin, 20 mM PMSF, 100 ⁇ g/ml Aprotinin, recombinant protein(s) added to a final volume of 250 ⁇ l, and incubated at 4 degrees C on a nutator for 1.5 hrs.
  • the beads were then washed 3x with the same buffer, resuspended directly in Laemli buffer, and loaded on 10% SDS-PAGE gel. Retained NFAT DBD protein was visualized by Western blotting described below using R59 anti-NFAT DBD antiserum.
  • Transfection assays were performed by the DEAE-dextran technique. Typically, 10 7 Jurkat cells were transfected with 2 ⁇ g of the reporter, the same amount of ICER expression vector and treated 18 hrs posttransfection with phorbol ester (10 5 mg/ml) and ionomycin (1 ⁇ g/ml) for 48 hrs. Luciferase and chloramphenicol acetyltransferase assays and quantification methods are described elsewhere (Promega, (62)). The percent conversion of [ 14 C]chloramphenicol to its acetylated forms was quantified using ImageQuant (Molecular Dynamics).
  • cotreatment with forskolin or 8-Br-cAMP reduced the cellular mRNA levels of IL-2, IFN ⁇ , TNF- ⁇ , and Lt ⁇ (Fig. 7A; lane 5 and 6, Fig. 7B; lane 5 and 6). It is believed that at least part of this transcriptional attenuation is based on cAMP-mediated expression of the transcriptional repressor ICER and a subsequent blockade of NFAT/AP-1 composite DNA sites essential for T helper- 1 cytokine expression.
  • the inhibition by ICER may occur either directly through binding to the DNA element or indirectly via protein-protein interactions such as to the rel homology domain of NFAT (NFAT DBD). 22
  • Example 10 Cyclic AMP-mediated Attenuation of T helper-1 Cytokine Transcription in Human Medullary Thymocytes Correlates with cAMP-mediated Induction of the Transcriptional Repressor ICER
  • ICER-mediated inhibition To test the mechanism involved in ICER-mediated inhibition, the presence of ICER protein in human medullary thymocytes after forskolin treatment was investigated to explore whether ICER interacts with important NFAT/AP-1 enhancer motifs of the IL-2, and IFN ⁇ promoters.
  • ICER Binds to NFAT/AP-1 Composite Sites of the lL-2 promoter To further address the mechanism by which ICER downregulates IL-2 gene expression the binding of bacteriall ⁇ expressed ICER to all five NFAT motifs of the IL-2 promoter reported to be essential for the full induction of the IL-2 gene [50] was examined (Fig 8A). Four out of five NFAT sites in positions (-90), (-135), (-160), and (-280) were previously characterized as NFAT/AP-1 composite sites due to their inherent ability to bind to the NFAT/AP-1 complex in a cooperative fashion (63).
  • NFAT-45 The fifth NFAT site in the most proximal position NFAT-45 does not bind to the NFAT/AP-1 complex and was determined to be exclusively an NFAT binding site (63).
  • ICER The strongest binding was observed to the NFAT/AP-1 composite sites in positions (-90) and (-160), an intermediate binding to the (-135) NFAT/AP-1 composite site, and weak binding to the most proximal and distal NFAT and NFAT/AP-1 sites in positions (-45) and (-280), respectively.
  • the binding specificity of recombinant ICER was evaluated using a CREM-specific antiserum (CS4) that "supershifts" ICER bound to specific oligonucleotides containing individually the five DNA motifs, leaving nonspecific binding unaffected (Fig. 8B, lanes 1-10) as well as by using control oligonucleotide encompassing the first 21 bp repeat (H21) of the HTLV-I LTR promoter containing the
  • NFAT DBD minimal DNA-binding domain of NFAT
  • NFAT ICER complex compared to ICER by itself (Fig. 8C, lanes 1-3). Because the NFAT -45 of the IL-2 promoter is the only one of the five sites examined without an adjacent AP-1 site, the finding that this site can form an NFAT/ICER complex suggests that ICER itself may tether to NFAT by a protein-protein interaction in addition to a protein-DNA action.
  • ICER Can Interact Directly with NFAT DBD
  • GST-pull down assays were performed using a GST-ICER fusion-protein linked to a Sepharose matrix in the presence of a truncated NFAT consisting of the DNA-binding domain (NFAT DBD) (Fig. 9, lane 1).
  • GST-ICER formed a complex with NFAT DBD as demonstrated by retention of NFAT DBD.
  • GST-CREB failed to associate with NFAT DBD under the same conditions (Fig. 9, lane 10).
  • NFAT oligonucleotide spanning mouse IL-4 NFAT, positions -69 to -79
  • AP-1 motif ap oligonucleotide spanning the human metallothionein ll A AP-1 site [MRE], positions -114 to -88
  • the (-280) motif of the IL-2 promoter known from NFAT studies as the principal site for binding of the NFAT/AP-1 complex, binds NFAT/AP-1 complexes effectively (61,66) showing little or no detectable formation of an NFAT/ICER complex (Fig. 8C, lanes 13-15).
  • the CD28RE (- 160 NFAT/AP-1 composite site) of human IL-2 promoter creates a ternary NFAT/ICER complex with an equal or slightly higher efficiency than the NFAT/AP-1 complex (Fig. 8D).
  • Example 16 NFAT/AP-1 Composite Sites in the context of the GM-CSF, IL-4, and TNF- ⁇ Promoters Bind ICER Either Alone or in Complexes NFAT/AP-1 binding sites have been shown previously to be essential for the efficient activation of the GM-CSF, IL-4, and TNF- ⁇ Promoters Bind ICER Either Alone or in Complexes NFAT/AP-1 binding sites have been shown previously to be essential for the efficient activation of the GM-
  • ICER can bind either by itself or in complexes with NFAT DBD to these composite sites in the promoters of the GM-CSF, IL-4, and TNF- ⁇ promoters, similar to the experiments using the binding site motifs of the IL-2 and IFN ⁇ promoters.
  • the GM-420 DNA motif strongly bound the purified NFAT/ICER complex (Fig. 11 B, lane 6), whereas the GM-
  • GM-420 motif has been shown to constitute the essential enhancer core of the GM-CSF promoter (52). Likewise,
  • NFAT/ICER readily formed a complex with the -80 element of the IL-4 and -95 element of the TNF-a promoter (Fig. 11 B, lane 12 and 15, respectively).
  • the ⁇ 3 motif of the TNF- ⁇ promoter which contains an "'inverted
  • NFAT may bind to the TNF- ⁇ motif as oligomers.
  • the binding of ICER to the oligonucleotides containing the NFAT/AP-1 composite sites is inhibited by competition of the binding with a CRE- containing oligonucleotide (Fig. 11 D, lanes 4, 7 and 10) or interference of the binding with antiserum to ICER (C-Ab)
  • ICER isoform II
  • ICER downregulated the human IL-2, CM-CSF, and TNF- ⁇ promoters 25 activated by the combined treatment of the cells with PMA and ionomycin, whereas ectopic expression of neither isoform of ICER did not prove to have any significant effect on VP16-mediated transactivation of (3xGAL4)-CR-CAT under the same conditions (Fig. 12).
  • ICER can be induced by, and substituted for, forskolin in the transcriptional downregulation of the calcineurin-dependent, NFAT/ AP-1 -mediated transactivation of IL-2, GM-CSF, and TNF- ⁇ promoters, when induced by PMA and ionomycin.
  • T cells (35).
  • protein kinases required for T cell proliferation were found to be insensitive or to exhibit a delayed response to high levels of intracellular cAMP (35).
  • the above results indicate that in human medullary thymocytes expression of the transcriptional repressor ICER correlates with a delayed cAMP-mediated transcriptional attenuation of T helper- 1 cytokine responses.
  • ICER a potential indirect role of ICER has been demonstrated in transgenic mice overexpressing the dominant negative CREB mutant (a functional homologue of ICER), which impairs the expression of IL-2 in thymocytes (73). Since the induction of IL-2 and IFN ⁇ expression is dependent on the activity conferred by each of the individual DNA motifs (51, 63), demonstration of a direct binding of ICER and/or the formation of an inhibitory NFAT/ICER complex on any of these NFAT/AP-1 composite sites could provide an explanation for the mechanism involved in the transcriptional attenuation of IL-2 and IFN ⁇ expression mediated by cAMP.
  • ICER may play an important role in transcriptional attenuation of GM-CSF expression. Similar binding studies performed with several NFAT/AP-1 composite sites important in the context of IL-4 and TNF- ⁇ promoters show that these sites, previously shown to be essential for efficient expression (52, 54, 56), bind ICER either alone or in complexes similarly to the motifs of the IL-2 and IFN ⁇ promoters. It remains to be determined whether the induction of
  • ICER can selectively modulate T helper-1 versus T helper-2 cytokine expression in peripheral lymphocytes.
  • ICER-containing complexes that are immunoreactive to ICER-supershifting antisera are efficiently competed by oligonucleotides containing CRE or NFAT motifs.
  • NFAT antisera which are unable to recognize directly bound ICER still affect the mobility of ICER-containing complexes, suggesting the possibility of the formation of NFAT/ICER complexes in vivo.
  • ICER inducible ICER expression in developing human medullary thymocytes as well as in certain subset(s) of human peripheral blood lymphocytes (36) and monocytes (work in progress) could significantly influence their respective effector functions(s).
  • the proposed inhibitory effects on effector function of the immune system mediated by ICER may be related to its ability to bind (mask) a wide range of CRE and AP-1 motifs and/ or its ability to inactivate certain transcription complexes via protein-protein interactions.
  • ICER inducible cAMP early repressor
  • ICER the only cAMP-inducible member of the CREB/CREM family of transcription factors, is a potent regulator acting in response to the cAMP/PKA signal transduction pathway to repress expression of specific cytokine genes in T lymphocytes (76, 77).
  • IL-2 interleukin-2
  • IL-5, IL-10, and IL-13 can be either susceptible or resistant to cAMP-mediated inhibition in human peripheral blood T lymphocytes polarized toward T helper 1 and T helper 2 dominant phenotypes in vitro.
  • forskolin a well known cAMP-elevating agonist, causes a dramatic transcriptional attenuation of early expression of numerous immunoregulatory cytokines and chemokines. This cAMP-mediated transcriptional attenuation tightly correlates with induction of ICER.
  • transgenic mice expressing ICER under the control of lymphocyte-specific lck promoter were generated. Upon stimulation, transgenic thymocytes expressing high levels of
  • ICER failed to express IL-2 and IFN- ⁇ as well as MIP-1 ⁇ and MlP-l ⁇ . Moreover, T cells from transgenic spleen exhibited conditional defect in proliferation resembling anerg ⁇ accompanied by the lack of allogeneic response in mixed lymphocyte reaction suggesting that ICER-mediated transcriptional attenuation of cytokine and chemokine expression may play an important role in inactivation of T cell effector functions.
  • ICER inducible cAMP early repressor belonging to the CREB (78) and CREM (79) family of the basic-leucine zipper transcription factors (80), acts as a dominant negative regulator of the cyclic AMP-dependent protein kinase A (cAMP/PKA)- signal transduction pathway (81 ).
  • ICER was originally described in the pineal gland as a powerful repressor of cAMP-induced transcription driven by rhythmic adrenergic signals originated from the endogenous clock
  • ICER has been thought to be expressed exlusively in the hypothalamo- pituitary-gonadal axis until discovered in the immune system where it was proposed to act as a potent modulator of T cell effector functions (76). Importantly, ICER represents the only known cAMP-inducible subfamily among CREB/CREM transcription factors.
  • ICER consists of four different isoforms generated by alternative splicing of its transcript (ICERI, ICERI ⁇ , ICERII, ICERII ⁇ )(81), with alternating exon- ⁇ , encoding either CREB-like (ICERI) or CREM-like (ICERII) DNA-binding domains.
  • Alternative splicing allows, after translation, a promiscuous binding of ICER proteins to a wide variety of cyclic responsive elements (CREs) and CRE-like DNA motifs which are regularly occupied by ubiquitiously expressed CREB and/or related transcription factors containing homologous basic leucine zipper (bZIP) domains such as members of CREM, ATF, Fos, and Jun families (84, 85).
  • CREs cyclic responsive elements
  • bZIP homologous basic leucine zipper
  • ICER subfamily represents a natural truncation of full length CREM due to its use of an alternative P2 promoter located in the middle of CREM gene. Therefore, ICER subfamily lacks the upstream transactivation domain of CREM transcription factors, since transcription of ICER starts downstream of the transactivation domain of CREM and possesses mainly CREB-like or CREM-like DNA-binding domains (81 ).
  • CREM transactivation domain highly homologous to transactivation domain of CREB, is believed to be responsible for failure of ICER to recruit CREB-binding protein/p300 (CBP/p300) (86, 87) which predetermines ICER to serve as a potent transcriptional repressor (88) opposing CREB mediated transcription (80).
  • CBP/p300 CREB-binding protein/p300
  • iigands such as prostanoids, chemokines, and hormones, many of them, including prostaglandin E 2 (PGE 2 ) receptor
  • PGE 2 prostaglandin E 2
  • T cells 89
  • These receptors often activate 28 cAMP/PKA as well as numerous other signal transduction pathways leading to phosphorylation on the Ser-133 residue of CREB (90-92) which allows phospho CREB (or its homologues (93, 94)) anchored on CREs of different promoters to recruit CBP/p300 complex involved in the variety of T cell responses including proliferation, differentiation or hormonal responses (86, 95, 96).
  • ICER can be induced in parallel through CRE-like autoregulatory responsive elements (CAREs) located in its intromc P2 promoter in the middle of CREM gene (97).
  • ICER protein has a capacity to compete with CREB for binding to numerous CRE like DNA binding motifs including
  • ICER's own CAREs in the P2 promoter eventually leading to its own downregulation.
  • CRE motif of the c-fos promoter in the position ( 60) 88, 98. Therefore, it is possible that ICER may first inhibit genes involved in T cell activation and/or proliferation (99) before shutting down its own expression (97).
  • the stability, binding, and trafficking of ICER protein in combination with inherently cyclical nature of its expression might explain delicate balance directing conditional character of cAMP-mediated transcriptional attenuation.
  • ICER is the only known cAMP-inducible isoform of CREM expressed in T lymphocytes (76, 77). Since cAMP mediated expression of ICER reaches extremely high levels in T cells, ICER can effectively compete and thereby repress transcription mediated by ubiquitously expressed CREB. Such competition is presumably even more efficient in T cells since they do not express potentially abundant isoforms of CREM constitutively expressed in stage specific fashion in numerous tissues of h ⁇ pothalamo pituitary-gonadal axis (100-102).
  • ICER competition with CREB may lead ultimately to uncoupling of CREB mediated recruitment of CBP/p300 since ICER does not possess transactivation domain without which, at least in the context of CREB/CREM family of transcription factors, recruitment of CBP/p300 complex is unlikely. Consequently,
  • ICER binding may lead to uncoupling of CBP, which abrogates early stages of transcriptional initiation due to the lack of CBP-associated histone-acetyl-transferase (HAT) activity resulting in the failure to maintain transc ⁇ ptionally competent conformation of chromatm (103, 104).
  • CBP-associated histone-acetyl-transferase (HAT) activity resulting in the failure to maintain transc ⁇ ptionally competent conformation of chromatm (103, 104).
  • HAT histone-acetyl-transferase
  • CRE-like motifs adjacent to NFAT or NFKB binding motifs may, in the context of cytokine promoters, anchor CBP in order to facilitate crosstalk between Rel- and bZIP-mediated transcription.
  • ICER binds DNA motifs critical for IL-2 expression either directly or indirectly via protein-protein interaction with Rel homology domain of NFAT (77).
  • CD28RE CD28-respo ⁇ s ⁇ ve element
  • CD28RE motif which in the context of IL-2 promoter has the highest affinity for ICER binding
  • T helper cells are not homogenous population but can be subdivided on the basis of cytokine expression into at least two subsets termed T helper 1 (Thi ) and T helper 2 (Th2)(1 14-116). Thi secrete IL-2 and INF- , while Th2 cells produce IL-4, IL-5, IL-10, and IL-13. There is now an abundant evidence that the ratio of Thi to Th2 cells is highly relevant to the outcome of a wide variety of syndromes including autoimmune, allergic, and infectious diseases
  • chemokines have been identified as attractants for different types of blood leukocytes to sites of infection and inflammation (120, 121). They are produced locally in the tissues and act on leukocytes through selective receptors. The differential expression of chemokine receptors may dictate, to a large extent, the migration and tissue homing of Thi and Th2 cells (122, 123). It may also determine different susceptibility of Th1 and Th2 cells to human immunodeficiency virus (HIV) strains using different fusion coreceptors (124, 125). Therefore, chemokines are part of effector and amplification mechanisms of polarized Th1- and Th2-mediated immune responses and their receptors might serve as Thi versus Th2 markers, as well as targets for selective modulation of T cell dependent immunity.
  • HAV human immunodeficiency virus
  • ICER was previously shown to downregulate IL-2 expression in transient tranfection assays (76, 77), it remained to be shown that this could be also the case in vivo. Analysis of ICER transgenic mice confirmed that
  • ICER itself, rather than elevated levels of intracellular cAMP, may direct cAMP-mediated transcriptional attenuation of IL-2 expression as well as expression of numerous cytokines including certain chemokines.
  • the results obtained herein correlate with reported observations in mice made transgenic with dominant negative mutant of CREB created by single point substitution of Ser-133 residue to Ala which cannot be phosphorylated and thus is unavailable to support CREB-mediated transcription (126), presumably due to the impaired recruitment of CBP/p300.
  • These transgenic mice similar to ICER transgenic mice, fail to produce IL-2 accompanied by the defect in T cell proliferation (126).
  • T cells of mice expressing dominant negative mutant of CREB fail to proliferate even in the presence of exogenously added IL-2, in contrast to T cells overexpressing ICER which upon addition of IL-2 are capable to partially correct the proliferative defect (data not shown).
  • Lack of IL-2 production accompanied by defect in T cell proliferation is a hallmark of graft versus host disease resulting in the development of marked immune dysfunction (127, 128).
  • ICER transgenic splenocytes in allogeneic mixed lymphocyte reaction showed lack of proliferation suggesting that ICER has capacity to suppress their ability to undergo activation.
  • Stable polarization of peripheral blood T cells towards type I or type 2 phenotype after polyclonal activation Polarization was done according to Asselin et al (132). Briefly, PBMC from normal donors isolated from leukopak by density gradient centrifugation in Ficoll and put into culture (RPMI 1640 with L-glutamine, 5% heat- inactivated AB + serum (Sigma, St. Louis), penicillin, streptomycin, and sodium pyruvate.
  • PBMC peripheral blood mononuclear cells
  • PBMC peripheral blood mononuclear cells
  • IL Deerfield, IL programmed for minimized neutrophil contamination.
  • the leukopheresis concentrate was acquired in small volume collection chambers to reduce platelet contamination. This concentrate typically yielded 4 to 10 x 10 9 peripheral blood mononuclear cells, which were immediately washed in a large volume of citrate-anticoagulated normal saline to remove contaminant platelets and plasma.
  • the washed cells were resuspended in Ca 2+ /Mg 2+ -free, pyrogen-free HBSS (BioWhittaker, Walkersville, MD) and elutriated using a Model J-6 M centrifuge equipped with a JE-5.0 elutriation rotor operating at 1725 x g and 20 °C (Beckman Instruments, Palo Alto, CA). Cells were loaded at a 120 cc/min flow rate , and then fractions were collected using stepwise flow rates ranging from 120 to 140 cc/min to obtain lymphocyte-rich fractions. Fractions were accumulated in Life Cell tissue culture vessels (Baxter HealthCare) on ice to inhibit cellular adherence.
  • Lymphocyte fractions were further purified with density gradient centrifugation using pyrogen-free Ficoll-Hypaque (BioWhittaker) to remove red blood cells. Elutriated fractions were subjected to further separations described below then analyzed by flow cytometry analysis and immediately utilized in experiments. Preparation of negatively selected T cells from peripheral blood lymphocytes using superparamagnetic beads
  • PBL subpopulations were fractioned using superparamagnetic microbeads (Miltenyi Biotec, Auburn, CA).
  • the wash and incubation buffer was Ca 2* /Mg 2* free DPBS with 0.5% bovine serum albumin (Sigma Chemicals, Co, St. Louis) without EDTA maintained at 4 °C.
  • the indirectly labeled cells (negative selection of T cells) were applied on CS * column positioned on VarioMACS with 19G needle as a flow resistor and 30 ml wash fraction was collected. Typically, purity of negatively selected T cell population was around 95% of CD3 * cells (data not shown) with prevailing representation of CD4 * cells (75%) over CD8 + cells (20%).
  • purified T cell population was around 95% of CD3 * cells (data not shown) with prevailing representation of CD4 * cells (75%) over CD8 + cells (20%).
  • NK cells paramagnetic bead separation
  • CD3 + CD56 + double positive cells expressing both T and NK cell markers, CD19 * B lymphocytes, and CD14 * monocytes could be detected (data not shown).
  • PBLs were analyzed before and after the separations on the MACS columns using fluorescent multicolor flow cytometry (FACSort, Becton Dickinson).
  • FACSort Fluorescence-Activated Cell Sorting
  • Fluorescein isothiocyanate (F ⁇ TC)-conjugated mouse anti-human CD3 and phycoerythrin (PE)-conjugated mouse anti- human CD16 purchased from PharMingen (San Diego, CA), PE-conjugated mouse anti-human CD19 from DAKO A/S (Denmark), FITC-conjugated mouse anti-human CD16 was purchased from Medarex Inc.
  • Cells were metabolically labeled with 5 S Translabel (ICN Biomedicals, CA) according to established protocols and lysed in RIPA buffer (0.15M NaCl, 50 mM Tris-CI pH 7.2, 1 % Triton X-100, 1 % Sodium Deoxycholate, 0.1 % SDS) supplemented with Complete, protease inhibitor cocktail (Boehringer Mannheim, Germany), clarified by centrifugation at 14,000 rpm for 30 min at 4 °C and precleared using Protein A Sepharose 4B beads (Pharmacia,
  • Immune complexes were collected onto Protein A Sepharose 4B beads that were pre-bound with CS4 CREM-specific antiserum, rocked for 30 min at 4 °C and followed by three washes with the RIPA buffer. Immune complexes were eluted from beads with Laemmli sample buffer and resolved by 15% SDS-PAGE under reducing conditions. The 35 S-signal was enhanced by PPO (2,5 diphenyloxazol, Sigma, St. Louis) treatment of the gel. 35 S-Labeled proteins were detected using 0-XAR films (Eastman Kodak, MA) exposed for 1 to 10 days at -70 °C.
  • RNA extraction was performed using RNeasy kit (Qiagen).
  • the RNA probe for ICER was generated from pJL5 by Xhol or Xbal digestion which corresponds to full-length cDNA of human ICERII described previously (76).
  • RNA probes I.AP03 and mAP03 were purchased from PharMingen (San Diego, CA) and labeled with [ ⁇ - 32 P] UTP using 32 reagents from an RNA probe kit (Ambion). These probes were used for RNase protection studies according to the protocol provided by Ambion (RPAII Ribonuclease Protection Assay kit).
  • a 0.36 kb fragment encompassing the ICER coding sequence driven by the proximal lck promoter was introduced in the germline of mice by pronuclear microinjection (158). Out of several independent founder lines generated, three were selected for analysis based on the level of expression of the transgene. For measurements of lymphocyte proliferation, freshly isolated lymphocytes (2x105) were cultured in triplicate in 200 ⁇ l DMEM medium with 10% FCS (GIBCO-BRL) in 96 well tissue culture plates (Falcon).
  • Lymphocytes were activated for 48 hours at 37 oC by treatment with PMA (10 ng/ml) and ionomycin (1 ⁇ g/ml), the anti-CD3 mAb, 145.2C11 (10 ⁇ g/ml immobilized on plastic tissue culture plates), or ConA (2 ⁇ g/ml). 48 hours after activation cells were labeled for 18 h by incubation in 3H-thymidine-containing tissue culture medium (1 ⁇ Ci/ml; specific activity 2 Ci/mmol) (Amersham). Cells were collected onto glass fibre filter mats and 3H-thymidine incorporation was measured in scintilation counter.
  • splenocytes from ICER transgenic or nontransgenic mice were cocultivated either with syngeneic splenocytes from CB57BL/6 mice or allogeneic splenocytes from BALB/c for 48 hrs then labeled and counted as described above.
  • Example 18 Human Peripheral Blood T Lymphocytes are Potent Inducers of ICER Protein
  • ICER mRNA can be induced by cAMP elevating agonists (e.g. forskolin or PGE2 ) in developing as well as mature T lymphocytes (76).
  • cAMP elevating agonists e.g. forskolin or PGE2
  • the presence of ICER protein was monitored by immunoprecipitation of the lysate prepared from human peripheral blood T lymphocytes at different time points following treatment with forskolin or PGE2 (Fig. 13). Immunoprecipitations of the whole cell extracts confirmed stability of ICER protein, its efficient labeling and continuous accumulation in the cell depending on elapsed time after the treatment.
  • ICERII, ICERI ⁇ , and ICERII ⁇ are the only cAMP inducible members of CREM family detectable in human peripheral blood T lymphocytes (Fig. 13).
  • ICER can be readily induced in peripheral blood T lymphocytes during isolation most likely through release of numerous cAMP-elevating agonists (data not shown).
  • combination of elutriation and negative selection allowed us to isolate 'untouched' peripheral blood T lymphocytes without elevated levels of ICER prior to forskolin stimulation (Fig. 13).
  • untreated T lymphocytes isolated by 33 negative selection see below
  • Example 19 Stable Polarization of Peripheral Blood T Cells Towards T helper -1 and T helper -2 Phenotypes Polarization of T helper effector functions, implicated in numerous diseases, represents potentially powerful intervention for directing immune responses via an adoptive therapy.
  • T helper-1 Thi
  • Th2 T helper-2
  • cytokine and chemokine expression following restimulation originates most likely from memory T cells judging from acquisition of their ability in both Thi and Th2 subsets to produce INF- ⁇ (Fig. 14B) which is a fundamental property of memory T cells (131).
  • Example 20 Cvclic-AMP-mediated Transcriptional Attenuation of Cytokines and Chemokines Expressed in Th1 and Th2 Dominant Subsets Correlates with Induction of ICER
  • ICER has a capacity to interact with NFAT in the context of CD28RE of IL-2 promoter either by direct protein-protein interaction or indirectly via DNA binding to the adjacent AP-1 motif (77).
  • ICER may form inactive NFAT/ICER complex which could lead to inhibition of NFAT-driven cytokines such as IL-2 has been previously tested in transient transfection assays (76, 77).
  • cAMP-mediated inhibition of endogenously expressed cytokines characteristic for Th1 and Th2 phenotypes tightly correlates with forskolin-mediated induction of ICER in both subsets suggesting that ICER could be responsible for observed inhibitory effect in cAMP-mediated transcriptional attenuation of cytokine expression.
  • early expression of chemokines which was found to be T helper-specific is also susceptible to cAMP- mediated inhibition for both MIP1 ⁇ and MIP1 ⁇ but not RANTES, and correlates inversely with ICER induction (Fig.
  • Example 22 Defective Production of IL-2 and INF- ⁇ as well as MIP-1 ⁇ and MIP-1 ⁇ Accompanied by Impaired T Cell Proliferation in Transgenic Mice Expressing ICER
  • ICER transgenic mice expressing human homologue of ICERII isoform preferentially in lymphoid cells under the control of proximal lck promoter, sustains high levels of ICER expression in transgenic thymus as confirmed by immunoprecipitations using CREM-specific antiserum (Fig.
  • ICER transgenic mice failed to express MIP-1 ⁇ and MIP-1 ⁇ as well as lymphotactin (Ltn) and IP- 10 while expression of RANTES, although modest, was almost unaffected suggesting high specificity of ICER- mediated inhibition in both induced as well as background cytokine or chemokine expression (Fig. 16B).
  • ICER expression was investigated.
  • ICER expression did not noticeably disrupt T cell development.
  • ICER transgenic splenocytes and peripheral blood lymphocytes displayed various extent of proliferation defect following activation using ConA, immobilized anti-CD3 monoclonal antibody 2C11 or phorbol ester 36 plus ionomycin treatment (Fig. 17B).
  • phorbol ester plus ionomycin treatment exhibited significant yet not as striking differences in proliferation in spleen of ICER transgenic mice (Fig. 17B).
  • ICER may play an important role in cAMP-mediated inhibition of cytokine and chemokine expression through modulation of IL-2 expression.
  • allogeneic stimulation in mixed lymphocyte reaction using splenocytes from ICER transgenic or nontransgenic mice cocultivated with either syngeneic splenocytes from CB57BL/6 mice or allogeneic splenocytes from BALB/c mice yielded dramatically different thymidine uptake suggesting that ICER transgenic splenocytes are phenotypically and functionally distinct from nontransgenic splenocytes (Fig. 17C).
  • ICER transgenic lymphocytes are functionally inactivated.
  • ICER is capable of binding to numerous NFAT/AP-1 motifs essential for cytokine expression in vitro, it remained to be shown that this binding is also reflected by transcriptional attenuation of the endogenous cytokine expression in vivo.
  • Our findings in ICER transgenic mice tightly correlate with previously reported observations in mice made transgenic with dominant negative mutant of CREB which due to the substitution of Ser 133 residue to Ala cannot be phosphorylated and thus unable to produce IL-2 which is accompanied by severe defect in T ceil proliferation (126), presumably due to its impaired ability to recruit transcriptional integrator CBP/p300.
  • CBP-deficient mice show general proliferation defect (96) supporting the notion that ICER (or dominant negative mutant of CREB) can compete with endogenously expressed CREB and thus abrogate recruitment of CBP/p300.
  • ICER is the only known cAMP-inducible transcriptional repressor which is in T lymphocytes physiologically relevant (76, 77). Furthermore, induction of ICER tightly correlates with cAMP-mediated transcriptional attenuation of IL-2 expression, usually accompanied by lack of T cell proliferation. Although it is unlikely that ICER alone can effectively compete with activated complex containing phospho-CREB associated with CBP/p300, it is possible that after disintegration of the complex in the absence of IL-2, ICER might be able to compete with CREB alone, thus undermining transcriptional competence for next round of transcriptional activation.
  • CBP/p300 which could make CD28RE motif unresponsive resulting in the lack of IL-2 expression.
  • ICER induction in response to PGE 2 may lead in the absence of IL-2 production to reported PGE 2 -mediated suppression of T cell effector functions (77, 134).
  • IL-2 receptor- mediated activation of PI3-kinase may relay signals required for activation of p70 rs kinases which are responsible for growth factor-mediated phosphorylation of CREB (98, 141, 142). Subsequent transcriptional induction is thought to proceed via the CBP/p300-dependent recruitment of RNA polymerase II complexes.
  • IL-2-mediated autocrine loop induced by phorbol ester and ionophore may render T cells resistant to cAMP-mediated inhibition even in the presence of ICER due to yet unidentified modification(s) of ICER and/or CBP/p300 activatory complex which, once assembled, might be unrestrained by actions of ICER, in contrast to the situation prior to recruitment of CBP when ICER on CRE sites could be sufficient for effective competition with CREB (77, 80).
  • ICER-mediated defect in T cell proliferation can be at least in part restored by the exogenousi ⁇ added IL-2 (data not shown) in striking contrast to the inability of IL-2 to rescue T cell proliferation in cells made transgenic by dominant negative mutant of CREB (126).
  • ICER is likely to be tightly regulated due to the cyclical nature of its expression which corresponds to actual physiological conditions in the cell (143). This is in striking contrast to the dominant negative mutant of CREB which is extremely stable irrespective of physiological conditions in the cell due to the inherently stable properties of ubiquitously expressed wild type CREB (80). Therefore, ICER-mediated conditional defect of T cell proliferation seems to be critically dependent on nature of restimulation reflecting differential activation of numerous signal transduction pathways involved in T cell costimulation in ICER transgenic mice.
  • conditional character of ICER-mediated defect in T cell proliferation suggests that ICER may represent tightly controlled molecular target regulated by sophisticated network of signal transduction pathways relaying their effects through postranslational modifications affecting ICER's capacity to function.
  • One reason for tight scrutiny might be due to ICER's ability to bind CD28RE
  • ICER binding may abrogate IL-2 production and lead to subsequent disruption of IL-2-mediated autocrine loop which could be critical for further modifications of CBP/p300 complex responsible in T cells for progression through cell cycle (144-148).
  • modifications of CBP/p300 complex in the presence of IL-2 may render T cells resistant to cAMP-mediated inhibition of cytokines in striking contrast to their susceptibility in the absence of IL-2 production.
  • NFAT and NFKB are often associated with bZIP transcriptional factors such as CREB, Fos, and Jun which in turn are responsible for recruitment of CBP/p300 (86, 151 ).
  • ICER actions could be either direct, for example by binding to unoccupied CD28RE motifs in the promoter context of critical cytokines and chemokines such as IL-2 (77) 38 and RANTES (152), or indirect, by downregulation of Fos and Jun expression through CRE-like motifs located in their respective promoters (98, 153, 154).
  • critical cytokines and chemokines such as IL-2 (77) 38 and RANTES (152)
  • CRE-like motifs located in their respective promoters
  • ICER transgenic lymphocytes had an enhanced instability in T cell proliferation defect observed independently on nature of costimulation.
  • One possible explanation might be induction of endogenous expression of activatory leucine zipper family member(s) which might be responsible for amelioration of ICER-mediated defect.
  • Similar situation in the case of CREB deficient mice, leads reportedly to expression of activatory CREM isoform(s), which over the time, completely compensated for observed defects (155).
  • ICER transgenic mice we did not detect any significant compensatory expression of CREM isoforms perhaps due to inability of CREM-specific P1 promoter to function in T lymphocytes (data not shown).
  • ICER's ability to mask critical CD28RE motifs may lead to failure to recruit CBP/p300 which would affect highly cooperative interactions on IL-2 promoter leading to subsequent disruption of IL-2-mediated autocrine loop. Absence of IL-2 production results then in abrogation of cytokine production associated with defect in T cell proliferation as observed in ICER transgenic mice.
  • ICER transgenic lymphocytes constitutively expressing ICER from heterologous promoter might at 39 least in part function through their enhanced capacity to generate functional AP-1 complex (85) thought to be instrumental for highly cooperative assembly of transcriptional factors on IL-2 promoter directed by costimulation
  • ICER could bind vacant CRE-like DNA-binding sites instead of AP-1 complex and in parallel inhibit expression of AP-1 components. Since ICER lacks transactivation domain, competition with ubiquitously expressed CREB or Jun family members may prevent recruitment of CBP/p300 leading in the absence of CBP-associated HAT activity to transcriptional silencing of the relevant promoter(s).
  • ICER binding leading directly or indirectly to impaired function of AP-1 via transcriptional attenuation of Fos and Jun (10) may favor ICER-mediated cooperative interaction with Rel homology domain of NFAT as demonstrated in vitro by formation of inhibitory NFAT/ICER complex (77).
  • these events are likely to be mutually interdependent, they are likely to reflect conditional and temporal character of cAMP-mediated inhibition as well as its potential reversibility.
  • costimulation represents clearly a decisive moment for shaping proliferative response dictating either susceptibility or resistance to enviromental inhibitory stimuli modulated by ICER-mediated transcriptional attenuation.
  • costimulation signal derived by phorbol ester a known tumor promoting agent, may escape ICER-mediated inhibition since it activates events associated with tumorigenesis.
  • ICER is expressed prior to forskolin treatment in a freshly isolated subset of human peripheral blood NK ceils enriched for CD56 + cells, whereas in peripheral blood CD3 + T cells ICER is inducible and in CD19 * B cells its expression appears to be refractory to forskolin treatment.
  • T and NK lymphocytes increased expression of ICER correlated with decreased Fas ligand expression.
  • ICER binds specifically to the proximal NFAT DNA binding site of the Fas ligand promoter represented by one of the two NFAT motifs essential for NFAT-mediated Fas ligand expression.
  • proximal NFAT motif In the presence of the minimal NFAT DNA-binding domain the proximal NFAT motif allows ICER and NFAT to form a NFAT/ICER ternary complex in vitro. Moreover, in the activated 2B4 T cell hybridoma the proximal NFAT motif participates in the down-regulation of the Fas ligand promoter mediated by ICER.
  • T cell receptor (TcR)- ediated activation of T-cells can induce programmed cell death by a Fas-dependent pathway (159).
  • the T cell hybridoma 2B4.1 1, one model to study cell death in T lymphocytes, undergoes apoptosis when it is stimulated by its cognate antigen, monoclonal antibody to CD3 ⁇ , or phorbol ester-ionom ⁇ cin treatment (160, 161 ).
  • forskolin an activator of the cAMP/PKA pathway, results in antagonism of 40
  • Fas-dependent cell death regardless of the presence or absence of transgenic Bcl-2 (162). Furthermore it was shown that forskolin not only inhibits activation-induced cell death (AICD) but also suppresses expression of Fas ligand (FasL)
  • FasL is a type II transmembrane protein that is a member of the TNF superfamily. FasL-deficient gld mice and Fas-deficient Ipr mice with generalized iymphoproliferative disorder have a defect in antigen-stimulated apoptosis, strongly supporting the notion that Fas is involved in activation induced T cell apoptosis (165).
  • cAMP signaling is inhibitory to T cell proliferation and effector functions (166).
  • the diterpene forskolin is a known activator of cAMP/PKA signaling pathway acting via direct stimulation of adenylyl cyclase.
  • ICER can be induced in T lymphocytes in response to forskolin-mediated elevation of intracellular cAMP by the alternative utilization of an internal promoter in CREM gene (167, 168).
  • ICER is a potent transcriptional repressor of cAMP- responsive gene transcription that appears to serve as a negative regulator of the CREB and CREM family of transcription factors as well as other related bZIP family members.
  • the importance of CREB in fetal T cell development was recently demonstrated by impaired development of the ⁇ but not ⁇ , lineage in CREB deficient mice (169).
  • a dominant-negative form of CREB which is a functional homologue of ICER had unperturbed T cell development when expressed under a CD2 promoter but exerted a defect in thymocyte proliferation and IL-2 production (170).
  • the ICER isoforms represent a unique cAMP-inducible CREM subfamily of transcription repressors containing cAMP-response elements within its own internal P2 promoter. Due to autoregulation of the cAMP-inducible P2 promoter, the expression of transcriptional repressor ICER can be intrinsically rhythmical. The rhythmical expression of ICER was first described in the pineal gland and in the hypothalamic-pituitary gonadal axis (171 , 172). However, the P2 promoter of ICER is also differentially inducible in organs other than the pineal and hypothalamic- pituitary gonadal axis such as specific subsets of human lymphocytes (167, 168). Thus ICER by its differential expression in response to cAMP/PKA signaling in lymphocytes could be a candidate for regulating molecules such as FasL.
  • NFAT nerve factor of activated T cells
  • TcR-mediated FasL expression 173, 174.
  • FasL promoter Two sites within FasL promoter, proximal and distal, identified through DNase I footprinting (173), bind NFAT proteins from activated T cells. Although both sites appear important for optimal expression of FasL in activated T cells, these sites do not seem to be required for constitutive FasL expression in Sertoli cells suggesting that inducible and constitutive FasL expression could be regulated differently.
  • NFATp a possibly critical transcription factor involved in Fas-mediated apoptosis of activated T cells (175).
  • the proximal NFAT motif of the FasL promoter could associate with ICER in a fashion similar to that of the proximal NFAT motif of IL-2 promoter (168), as well as numerous NFAT/AP-1 composite DNA binding sites previously identified as 41 being essential in the context of IL-2, GM-CSF, IL-4 and TNF ⁇ promoters (168, 176-179).
  • NFAT-DBD minimal NFAT DNA-binding domain
  • NFAT/ICER ternary complexes in a fashion similar to those of the cytokine NFAT DNA binding sites interacting with
  • ICER either by protein-protein interactions via NFAT DBD, or by direct protein-DNA interactions via ICER. These considerations are consistent with, and further support, a hypothesis that ICER may act to regulate FasL expression.
  • ICER in transient transfection assays forskolin-mediated induction of ICER correlates closely with the ability of ectopically expressed ICER to repress activation of the FasL promoter as well as other NFAT-driven cytokine promoters such as IL-2, GM-CSF, and TNF (168).
  • NK lymphocytes under conditions used in our study, exhibit pre-existing levels of ICER prior to forskolin stimulation both on the mRNA and protein levels.
  • transcriptional de-repression of FasL expression reflected by cessation of ICER expression in phorbol ester activated NK lymphocytes, could implicate ICER in the modulation of FasL expression in a direct as well as an indirect fashion.
  • Elutriated PBLs were prepared as detailed previously (182) and briefly described below. Healthy volunteers provided informed consent to undergo leukapheresis and countercurrent centrifugal elutriation. All collection steps were performed with pyrogen-free reagents. Each donor was initially leukopheresed 5 to 7 liters whole blood on a Fenwal CS3000 blood cell separator (Baxter HealthCare Corp. Deerfield, IL) programmed for minimized neutrophil contamination. The leukopheresis concentrate was acquired in small volume collection chambers to reduce platelet contamination.
  • This concentrate typically yielded 4 to 10 x 10 9 peripheral blood mononuclear cells, which were immediately washed in a large volume of citrate-anticoagulated normal saline to remove contaminant platelets and plasma.
  • the washed cells were resuspended in Ca 2* /Mg * -free, pyrogen-free HBSS (BioWhittaker, Walkersville, MD) and elutriated using a Model J-6 M centrifuge equipped with a JE-5.0 elutriation rotor operating at 1725 x g and 20 °C (Beckman Instruments, Palo Alto, CA) (183, 184).
  • PBL subpopulations were fractioned using superparamagnetic microbeads (Miltenyi Biotec, Auburn, CA) preconjugated with mouse anti-human mAbs to either CD3, CD19 or CD56 for positively selected cells, while negatively selected T cells were prepared by using a cocktail of hapten-bound mAbs with specifity for cell surface markers expressed by non-T cell populations (anti-CDI lb, CD16, CD19, CD36, and CD56), with subsequent incubation of superparamagnetic anti-hapten microbeads.
  • the wash and incubation buffer was CaNMg 2* free DPBS with 0.5% bovine serum albumin (Sigma Chemicals, Co, St. Louis) without EDTA maintained at 4 °C.
  • the directly labeled cells (CD3 * , CD19 ⁇ or CD56 * ) were applied on VS + columns positioned on MidiMACS magnet (2.5 x 10 8 cells per column). After four 3 ml washes, columns were removed from the magnets and positively selected cells were flushed out with 5 ml of the buffer per column. Cells were evaluated for expression of CD3, CD19, and CD56 cell surface molecules by multicolor flow cytometry. Typically, purity of CD3 + T cell, CD19 * B cell, and CD56 * NK cell populations was higher than 95% (data not shown) with significant (about 10%) representation of CD3 * CD56 * double positive cells expressing both T and NK cell markers in the case of CD3 * T cells and CD56 * NK cells.
  • PBLs were analyzed before and after the separations on the MACS columns using fluorescent multicolor flow cytometry (FACSort, Becton Dickinson).
  • FACSort Fluorescein isothiocyanate
  • PE phycoerythrin
  • FITC-conjugated mouse anti-human CD 16 was purchased from Medarex Inc.
  • PE- conjugated mouse anti-human CD56, FITC-conjugated mouse anti-human CD4, TRI color (TC)-conjugated mouse anti- human CD3, CD8, CD14 and FITC-, PE-, as well as TC- conjugated IgG subclass matched control antibodies were purchased from Caltag Laboratories (Buriingame, CA). Cells were stained at 4°C using Ca 2* /Mg 2* free DPBS with 43
  • the NK3.3 human NK cell line (gift from Dr. J. Kornbluth) was maintained in RPM1 1640 with 25 mM Hepes,
  • NK92 human NK cell line (gift from Dr. E. Long) were maintained in Myelocult H5100
  • 2B4.11 T cell hybridoma (gift from Dr. J. Ashwell) was grown exponentially in RPM1 1640 (for luciferase assay purposes without phenol red) with 10 % heat inactivated fetal bovine serum, penicillin (Gibco, BRL), and gentamicin (Gibco, BRL).
  • Immune complexes were eluted from beads with Laemmli sample buffer and resolved by 15% SDS-PAGE under reduced conditions. The 35 S-signal was enhanced by PPO (2,5 diphenyloxazol, Sigma, St. Louis) treatment of the gel. 5 S-Labeled proteins were detected using 0-XAR films (Eastman Kodak, MA) exposed for 1 to 10 days at -70 °C.
  • RNA extraction was performed as described (Qiagen).
  • the RNA probe for ICER was generated from pJL5 by
  • RNA probes hAP03 and mAP03 were purchased from PharMingen (San Diego, CA) and labeled with [ ⁇ - 3 P] UTP using reagents from an RNA probe kit (Ambion). These probes were used for RNase protection studies according to the protocol provided by Ambion (RPAII Ribonuciease Protection Assay kit).
  • ICERII cDNA was subcloned into the pGEXKG vector (Pharmacia) and expressed in bacteria as a GST- fusion protein. Purification of ICER was carried out with minor modifications according to the protocol previously established for CREB (187). NFATpXS(1-187) encompassing the minimal DNA-biding domain of NFATp (gift from Dr.
  • Rao was expressed in bacteria as a hexahistidine-tagged protein and purified as reported previously (180).
  • Binding reactions were performed in a 15 ⁇ l reaction volume containing 20 mM HEPES, 1 mM MgCI 2 , 50 mM KCl, 12% glycerol, 0.1 mM EDTA, 0.5 mM DTT, 0.2 ⁇ g poly (dl-dC) as an non-specific competitor, and 44 recombinant proteins as indicated.
  • 32 P-labeled oligonucleotides were added and incubated for 10 min at room temperature. Samples were run on a 4% polyacrylamide gel in 0.5 x TBE at 200 V for 2 h following a 2 h pre-run at 4°C. The dried gels were exposed for autoradiography overnight.
  • the oligonucleotides encompassing NFAT composite sites of the following human promoters were used: SEQ ID NO. 15: FasL prox 5'-gatccTAGCTATGGAAACTCTATAa-3'
  • SEQ ID NO. 16 FasL dist 5'-gatccCTGGGCGGAAACTTCCAGGa-3' SEQ ID NO. 17.
  • IL-2 (-160) 5'-ctagaAAAGAATTCCAAAGAGTCATCAGAAa-3'; SEQ ID NO. 37
  • GM-CSF (-420) 5'-gatccCATCTTTCTCATGGAAAGATGACATCAGGGAa-3'; Lower case letters indicate overhangs for Spel/Xbal recognition sites (IL-2) or BamHI/Bglll recognition sites (FasL, GM- CSF).
  • Transfection assays were performed by the modified DEAE-dextran technique in 96 well CulturPlates (Packard, NJ) coated or not with antiCD3 monoclonal antibody 2C11. Typically, 2 x 10 6 cells transfected with 2 ⁇ g of the reporter and the same amount of ICER expression vector were distributed into two wells precoated with 2C1 1 and two uncoated wells. After 12 to 16 hrs LucLite assay (Packard, NJ) was used for evaluation of luciferase activity and luminiscence was quantified on TopCount (Packard, NJ). Chloramphenicol acetyltransferase assays and quantification methods are described elsewhere (188).
  • ICER was not detectable in the control leukemic Jurkat T cell line prior to forskolin treatment (Fig. 18, 45 lanes 21 and 22) in agreement with RNase protection data (see Fig. 23B, lane 1) and only limited levels of ICER mRNA (Fig. 23B, lane 2) and protein could be detected after forskolin treatment in Jurkat T cells (Fig 18, lanes 23 and 24) indicating that signal detected in immunoprecipitations is ICER specific.
  • the differential regulation of ICER expression found in these studies supports the notion that ICER might act as a potentially important molecule in T lymphocyte function.
  • Example 24 Forskolin- mediated Transcriptional Attenuation of FasL Expression in Activated 2B4 T Cell Hybridoma as well as Human Peripheral Blood T Lymphocytes Correlates with ICER Induction
  • ICER is efficiently expressed in T cells.
  • 2B4 T cell hybridoma It was reported previously that forskolin can effectively counteract apoptosis in phorbol ester-ionomycin treated 2B4 hybridoma T cells (which in many respects mimics TcR-mediated activation triggering AICD due to potent up-regulation of FasL expression) by transcriptional attenuation of FasL expression (161 , 162).
  • Time course data in activated 2B4 T cell hybridoma indicate a tight correlation between down-regulation of FasL expression and induction of the potent transcriptional repressor ICER consistent with the possibility that forskolin-mediated ICER expression could cause transcriptional attenuation of FasL expression.
  • ICER expression in cells of NK lineage human lymphocyte populations enriched for CD56 * cells were evaluated. Interestingly, they were found to exhibit elevated levels of ICER mRNA prior to forskolin treatment with dramatic decrease of ICER mRNA after three hours of phorbol ester treatment which is coincident with induction of FasL, FAP (PNP1, protein tyrosine phosphatase 1E), and TRADD (TNF receptor-1 associated death domain protein) expression (Fig. 21).
  • FasL was dramatically increased after phorbol ester treatment while levels of ICER mRNA were decreased to background (Fig. 21 B).
  • NK cells correlate with elevated levels of ICER protein in human peripheral blood NK lymphocytes prior to forskolin treatment.
  • Fig. 22A CREM-specific antiserum
  • CD56 * NK cells as opposed to CD3 + T cells or CD19 * B cells and further supported the hypothesis that ICER may regulate FasL expression by the reciprocal balance of the expression of the two.
  • Example 26 Proximal NFAT Binding Site of the Fas Ligand Promoter Binds ICER Either Alone or in Complex with NFAT DBD
  • ICER Either Alone or in Complex with NFAT DBD
  • ICER binding specificity was evaluated using a CREM-specific antiserum (CS4) (168) that "supershifts" ICER bound to specific oligonucleotides containing individually proximal and distal NFAT motifs of Fas ligand promoter and two control NFAT/AP-1 motifs in the IL-2 promoter in position (-160) and GM-CSF promoter in position (-420) (Fig. 23A and B).
  • CS4 CREM-specific antiserum
  • Both of these control motifs can bind ICER either directly via AP-1 like sequence adjacent to NFAT motif and/or indirectly via interaction of ICER with NFAT DBD (168), which is both necessary and sufficient for NFAT DNA binding as well as complex formation with ICER (168) or AP-1 (181).
  • ICER and ICER containing complexes can be competed by unlabeled oligonucleotides containing CRE motifs (168).
  • proximal NFAT motif of the IL-2 promoter we observed specific direct binding of ICER to the proximal NFAT motif of the FasL promoter which in the presence of NFAT DBD yielded a 47 ternary NFAT/ICER complex (Fig.
  • the distal NFAT motif fails to support significant level of ICER binding and/or formation of NFAT/ICER ternary complex (Fig. 23C, lanes 4 to 6). Instead, the distal NFAT motif supports, at least in vitro, high affinity NFAT DBD binding accompanied by NFAT DBD dimer formation which is consistent with the proposed dominant role of distal NFAT motif in activation of Fas ligand expression (15, 16). These experiments provide further evidence supporting ICER as a regulatory molecule in FasL expression.
  • ICER expression can mediate the effect of forskolin in transcriptional attenuation of FasL promoter observed in 2B4 T cell hybridoma and peripheral blood T and NK lymphocytes.
  • ICERII, ICERII ⁇ , ICERI, and ICERI ⁇ were ectopically expressed in 2B4 hybridoma T cells in transient transfection assays.
  • Expression of ICER down-regulated both human FasL promoters with or without distal NFAT motif (Fig. 24A) activated by a monoclonal antibody 2C11 (with specificity for the CD3 ⁇ subunit of the CD3 complex) (Fig. 24B).
  • Ectopic expression of either isoform of ICER had no significant effect on VP16-mediated transactivation of (3xGAL4)- CR-CAT (168) (data not shown).
  • FasL reporter containing the proximal NFAT motif alone was found even more susceptible to ICER-mediated repression in accordance with the higher affinity of proximal NFAT motif for ICER binding and complex formation documented in gel shift assays (Fig. 23, and Fig. 23B).
  • ICER can be induced by, and substituted for, forskolin in the transcriptional down-regulation of FasL reporter induced by antiCD3 ⁇ stimulation in 2B4 T cells.
  • the mechanism of cAMP-mediated inhibition of FasL expression in activated T lymphocytes is correlated with cAMP-mediated induction of the powerful transcriptional repressor - ICER.
  • FasL promoter Footprinting and electrophoretic mobility shift analyses revealed two NFAT sites within FasL promoter, proximal (from -126 to -144), and distal (from -263 to -283) as essential for high levels of FasL expression in T lymphocytes (173, 174).
  • the role of NFAT in the activation of FasL promoter was further strengthened by the observations that activated T lymphocytes from NFATp knock out mice (175) failed to express FasL in T lymphocytes and showed typical signs of splenomegaly inherent to g/d mice models (165) suggesting that in T cell environment NFAT plays an important role in activation of FasL expression.
  • proximal NFAT motif in the IL-2 promoter (168)
  • the proximal NFAT site in the FasL promoter has the capacity to associate with NFAT DBD (181) and ICER to form inhibitory NFAT/ICER complex.
  • a FasL reporter containing the proximal NFAT motif alone is highly susceptible to ICER-mediated repression in transient transfection assays in agreement with the ability of ICER to bind the proximal NFAT motif either alone or in the complex with NFAT DBD.
  • ICER and FasL reporter were co-expressed in 2B4 T cells activated by antiCD3 ⁇ antibody. These transient transfections indicate that significant down-regulation of activated FasL promoter in 2B4 T cell hybridoma can be observed based on expression of different isoforms of ICER (ICERII, ICERII ⁇ , 48
  • ICERI, and ICERI ⁇ are examples of transcriptional repressor ICER that can be sufficient for the transcriptional attenuation of FasL promoter activated by antiCD3 ⁇ stimulation in 2B4 T cell hybridoma.
  • ICER inducible population of lymphocytes although background levels of ICER in positively selected CD3 * T lymphocytes are usually higher in comparison to T lymphocytes isolated by depletion strategy.
  • CD3 triggered ICER induction another possible explanation of this observation is related to the population of large granular lymphocytes expressing both T (CD3 + ) and NK (CD56 * ) cell markers on their surface (189) which could be retained amongst CD3 * positively selected T cells, contributing to elevated background levels of ICER.
  • T CD3 +
  • NK CD56 *
  • both positively and negatively selected T cell populations contain low numbers of contaminating cells which after phorbol ester and ionomycin treatment may contribute indirectly to the elevated levels of ICER (e.g. by release of cAMP agonists such as prostaglandins).
  • phorbol ester-ionomycin treatment in T cell lines such as 2B4 T cell hybridoma (Fig. 19A) or Jurkat T cell line (data not shown) does not yield ICER mRNA and these T cell lines require forskolin treatment for ICER induction.
  • NK cells show significant expression of ICER prior to forskolin treatment which could be responsible at least in part for ICER-specific signal detectable in elutriated peripheral blood lymphocytes observed before subsequent separations both on mRNA and protein levels.
  • Fas ligand-Fas pathway The engagement of stimuli involved in Fas ligand-Fas pathway in human NK cells have been mimicked for the purpose of this study by phorbol ester treatment leading to profound increase of Fas ligand expression accompanied by reported increased ability of NK cells to kill in cytotoxic assays (190). While phorbol ester-mediated Fas ligand expression is likely to be independent of NFAT-driven expression, cessation of ICER expression correlates with de- repression of Fas ligand expression.
  • NK cells may contribute to the ICER-specific signal
  • cessation of ICER expression and subsequent up-regulation of FasL expression is consistent with postulated repressive role of ICER in NK cells even in the absence 49 of NFAT function.
  • ICER acts as a transcriptional repressor of Fas ligand expression which could be effective under the circumstances when transcriptional factors other than NFAT are responsible for Fas ligand expression.
  • ICER may participate in transcriptional modulation of other yet unidentified transcription factors acting in trans on FasL promoter.
  • Inducible Leucine Zipper - GILZ correlates with dexamethasone-induced transcriptional attenuation of FasL expression which could lead to inhibition of AICD (191) in analogous fashion as ICER induction could lead to forskolin-mediated inhibition of AICD (161).
  • signaling through diverse agonists such as cAMP or dexamethasone leading ultimately to transcriptional attenuation of FasL promoter could be conferred in T lymphocytes by induction of at least two independent transcriptional repressors - ICER and GILZ.
  • ICER-mediated inhibition of immune cell activity may be involved in the progression of a variety of clinical conditions.
  • ICER-mediated inhibition of immune cell activity may contribute to the progression of conditions such as cancer or diseases resulting from infection with pathogenic organisms.
  • agents which reduce the level of ICER-mediated inhibtion of immune cell activity represent attractive therapeutics for treating conditions which result from or are exacerbated by the inhibition of immune cell activity.
  • agents which increase the level of ICER activity represent attractive therapeutics for treating conditions conditions which result from or are exacerbated by the over-activity of immune cells.
  • agents which reduce or increase the level of ICER-mediated inhibition of immune cell activity are valuable reagents for studying and characterizing the molecular mechanisms which govern the activity of immune cells and the progression of diseases resulting from or exacerbated by the inhibition of immune cell activity using in vitro or in vivo model systems.
  • ICER's involvement in the inhibition of immune cell activity may be further characterized as described below.
  • ICER ICER's involvement in tumor-mediated inhibition of immune cells
  • immune cells such as T lymphocytes, B lymphocytes, NK cells, monocytes, dendritic cells, and antigen presenting cells. 50
  • Substances obtained from or secreted by viable tumor cells, or obtained from killed tumor cells, tumor cell lysates, or supernatants from tumor cells are incubated with normal immune system cells such as T lymphocytes, B lymphocytes, NK cells, monocytes, dendritic cells, and antigen presenting cells.
  • normal immune system cells such as T lymphocytes, B lymphocytes, NK cells, monocytes, dendritic cells, and antigen presenting cells.
  • the immune activities of the cells are measured using standard techniques such as cytokine assays (to measure secreted cytokines), proliferation assays, stimulation assays, and target lysis assays.
  • ICER mRNA and protein The expression of ICER mRNA and protein is measured in the cells suppressed by tumors above to determine whether sustained ICER expression occurs during such inhibition.
  • ICER expression is measured in cells suppressed by tumors under conditions in which PGE2 is secreted or induced by tumor cells.
  • a variety of techniques, such as blocking antibodies, inhibitors of PGE2 receptors, etc. are use to determine which particular factors are responsible for such inhibition and sustained ICER expression.
  • ICER involvement in the inhibition of immune cell activity caused by infectious organisms may also be characterized using the procedures described above.
  • infectious pathogens pathogens are known to produce factors such as viral IL-10 or cAMP-stimulating factors (22,23) which inhibit immune cell acitivity.
  • substances obtained from or secreted by cells infected with a pathogenic organism or obtained from infected cells, infected cell lysates, or supernatants from infected cells are incubated with normal immune system cells such as T lymphocytes, B lymphocytes, NK cells, monocytes, dendritic cells, and antigen presenting cells.
  • normal immune system cells such as T lymphocytes, B lymphocytes, NK cells, monocytes, dendritic cells, and antigen presenting cells.
  • the immune activities of the cells are measured using standard techniques such as cytokine assays
  • ICER mRNA and protein are measured in the immune cells whose activity is suppressed by through the action of an infectious organism to determine whether sustained ICER expression occurs during such inhibition.
  • a variety of techniques, such as blocking antibodies, inhibitors of cytokine receptors, and other techniques familiar to those skilled in the art are use to determine which particular factors are responsible for such inhibition and sustained ICER expression.
  • agents which reduce or increase the level of ICER activity in immune cells may be used to characterize the mechanisms and factors involved in controlling immune cell activity using in vitro or in vivo model systems as well as to treat conditions characterized by or exacerbated by inhibition or stimulation of immune cell activity.
  • agents may be used to reduce or increase the level of ICER activity in immune cells such as T lymphocytes, B lymphocytes, NK cells, monocytes, dendritic ceils, and antigen presenting cells.
  • immune cells such as T lymphocytes, B lymphocytes, NK cells, monocytes, dendritic ceils, and antigen presenting cells.
  • agents include 51 ribozymes, antisense nucleic acids, triple helix forming nucleic acids, and other factors which increase or decrease transcription from the ICER promoter.
  • Ribozymes are RNA molecules which possess an endonuclease activity.
  • the ribozymes for use in reducing ICER activity levels contain one or more catalytic regions capable of cleaving one or more target sites in mRNAs encoding one or more ICER isoforms.
  • the ribozymes include one or more targetting regions which are complementary to one or more sequences in the ICER mRNA.
  • ribozymes Any of the types of ribozymes familiar to those skilled in the art may be used to reduce ICER activity levels.
  • ribozymes comprising a caatalytic core of nine bases, a double stranded step-loop structure, and two regions on either side of the catalytic core which are complementary to the target mRNA.
  • ribozymes such as those described in U.S. Patent No.
  • the ribozymes for reducing ICER activity levels may have multiple catalytic regions, such as those described in U.S. Patent No. 5,635,385.
  • the ribozymes may include one or more rigid linkers, such as those described in U.S. Patent Nos. 5,679,555 and 5,650,502 to increase their stability in vivo.
  • the ribozymes may include one or more 2'-0-alkylated nucleotides such as those described in U.S. Patent No. 5,545,729 to enhance their stability in vivo.
  • Example 29 describes the analysis of the ability of different ribozymes to inhibit T cell acitivity.
  • normal human T cells such as freshly isolated peripheral blood CD4 + T cells express ICER mRNA and ICER protein after exposure to the cAMP agonists forskolin and sustained ICER mRNA expression occurs after combined treatment with ionomycin plus forskolin.
  • Treatment of such T cells with cAMP-sti ulating agents or agonists such as forskolin or PGE2 also results in marked prolonged blockade of T cell proliferation whether the proliferation is stimulated by calcium ionophore or by specific antigenic restimulation.
  • the ability of ribozymes to reduce ICER-mediated inhibition of T cell activity may be measured by determining their ability to block the inhibition of T cells treated with forskolin, PGE2 or ionomycin plus forskolin.
  • a set of ribozymes having different catalytic sequences capable of recognizing different cleavage sites and/or different targetting sequences capable of directing the ribozyme to different sites ICER mRNAs encoding one or more ICER isoforms is designed using conventional techniques.
  • ribozymes incapable of cleaving ICER mRNA such as ribozymes having targetting sequences identical to the sequence of one or more forms of ICER mRNA such that they do not form a duplex with ICER mRNA may be used.
  • the control ribozyme may be a ribozyme which targets an mRNA other than an ICER mRNA.
  • the ribozymes are then prepared using any of the techniques familiar to those skilled in the art.
  • the ribozymes may be synthesized conventional chemical synthesis procedures.
  • the ribozymes may be prepared by performing an in vitro transcription reaction on a linearized vector comprising a nucleotide sequence encoding the ribozyme operably linked to a promoter.
  • the promoter directing the in vitro transcription reaction may be the T7 promoter or the SP6 promoter.
  • Each of the ribozymes are then introduced into the T cells at a range of concentrations.
  • the ribozymes may be introduced using any of the techniques familiar to those skilled in the art.
  • the ribozymes may be introduced into T cells as naked molecules.
  • the ribozymes may be introduced into the T cells using lipofection.
  • the effect of each ribozyme on ICER activity in T cells may be evaluated using a variety of systems. In one assay, the effect of each ribozyme on ICER activity in T cells is determined by quantitating its ability to reduce or disrupt the forskolin-induced inhibition of T cell proliferation.
  • T ceils are prepulsed with the ribozymes to be screened, or with combinations of ribozymes prior to exposure to cAMP-stimulating agents or agonists such as forskolin.
  • Immunoprecipitation and/or RNAse protection assays are performed to identify those ribozymes which are capable of potently blocking forskolin-induced ICER expression in these T cells.
  • the results obtained with each of the ribozymes being screened are compared to those in cells which received control ribozymes.
  • Ribozymes which reduce ICER expression levels or mRNA levels to a statiscally significant extent may be used as therapeutics or as reagents for studying the molecular mechanisms which govern immune cell activity.
  • the ribozyme which reduces ICER expression to the greatest extent is used as such a therapeutic or reagent.
  • ICER ribozymes may also be used to reduce or prevent ICER/cAMP-mediated inhibition of T cell cytokine secretion as well as cAMP-mediated inhibition of T cell signal transduction.
  • each ribozyme on ICER activity in T cells is determined by quantitating its ability to reduce or disrupt cAMP-induced suppression of T cell function using standard assays for measuring T cell proliferation, cytokine release asays, signal transduction and target lysis assays and comparing the results to those obtained with control ribozymes.
  • Those ribozymes which reduce ICER expression levels or mRNA levels to a statiscally significant extent may be used as therapeutics or as reagents for studying the molecular mechanisms which govern immune cell activity.
  • the ribozyme which reduces ICER expression to the greatest extent is used as such a therapeutic or reagent.
  • vectors comprising nucleotide sequences encoding each of the test ribozymes operably linked to a promoter are introduced into T cells, such as freshly cultured CD4 4 anti-TETANUS T cells.
  • the vector may comprise any of the vectors conventionally used to express nucleic acids in immune cells, including retroviral vectors (28,29), episomal vectors, vectors which are stably integrated into the genome of the host cell, or vectors which are transiently present in the host cell.
  • a vector encoding a ribozyme having targetting sequences identical to the sequence of one or more forms of ICER mRNA such that it does not form a duplex with ICER mRNA or a 53 ribozyme which targets an mRNA other than an ICER mRNA is introduced in the T cells.
  • ICER antibodies or RNAse protection assays is performed to measure the levels of ICER protein or intact ICER mRNA present in T cells containing vectors encoding each of the test ribozymes. The results are compared to the levels in T cells receiving control ribozymes.
  • Ribozymes which reduce ICER expression levels or mRNA levels to a statiscally significant extent may be used as therapeutics or as reagents for studying the molecular mechanisms which govern immune cell activity.
  • the ribozyme which reduces ICER expression to the greatest extent is used as such a therapeutic or reagent.
  • the ability of the ribozymes to inhibit T cell activity in vivo is determined as follows.
  • Test and control ribozymes are introduced into T cells using any of the above methods (i.e. naked nucleic acids, lipofection, and stable or transient expression vectors).
  • the T cells are then administered to same-strain tumor bearing mice to measure the ability of the ribozymes to inhibit ICER-mediated inhibition of the immune response.
  • the results obtained with each of the test ribozymes are compared to those obtained with the controls.
  • Ribozymes which reduce ICER-mediated inhibition of the immune response to a statiscally significant extent may be used as therapeutics or as reagents for studying the molecular mechanisms which govern immune cell activity.
  • the ribozyme which reduces ICER-mediated inhibition of the immune response to the greatest extent is used as such a therapeutic or reagent.
  • Ribozymes may also be used to reduce ICER-mediated inhibition of immune cell activity in immune cells other than T cells, such as B cells, NK cells, dendritic cells, or antigen presenting cells. Methods for identifying ribozymes which effectively reduce ICER-mediated inhibition of antigen presenting cell activity are described below. Example 30
  • ICER ribozymes are screened for the ability to reduce or prevent ICER-mediated inhibition of antigen presenting cells, such as monocytes or dendritic cells using the procedures described above for T cells.
  • cAMP- stimulating agents or agonists such as PGE2 and forskolin have been shown to have a variety of inhibitory effects on antigen-presenting cells (APC), including inhibition of IL-12 secretion and inhibited upregulation of the costimulatory molecule B7.1 (see above).
  • APC such as monocytes and dendritic cells (DC) are stimulated with cAMP stimulating agents and treated with the ICER ribozymes or control ribozymes as described in the T cell assays above.
  • ICER-mediated inhibition may be measured by measuring the PGE2/forskolin-induced inhibition of calcium-ionophore-stimulated CD80 (B7.1) expression in peripheral blood human monocytes (4).
  • Ribozymes which reduce the inhibition of antigen presenting cell activity to a statiscally significant extent may be used as therapeutics or as reagents for studying the molecular mechanisms which govern immune cell activity.
  • the ribozyme which reduces the inhibition of antigen presenting cell activity to the greatest extent is used as such a therapeutic or reagent.
  • ICER ribozymes to reduce or prevent the ICER-mediated inhibition of B lymphocyte activity may also be confirmed as follows.
  • ICER ribozymes and control ribozymes are transiently or introduced into B lymphocytes treated with cAMP agonists as described above.
  • Ribozymes which reduce the inhibition of B cell activity to a statiscally significant extent may be used as therapeutics or as reagents for studying the molecular mechanisms which govern immune cell activity.
  • the ribozyme which reduces the inhibition of B cell activity to the greatest extent is used as such a therapeutic or reagent.
  • ICER ribozymes to reduce or prevent the ICER-mediated inhibition of NK ceil activity may also be confirmed as follows.
  • ICER ribozymes and control ribozymes are transiently or stably introduced into NK cells treated with cAMP agonists as described above.
  • Ribozymes which reduce the inhibition NK cell activity to a statiscally significant extent may be used as therapeutics or as reagents for studying the molecular mechanisms which govern immune cell activity.
  • the ribozyme which reduces the inhibition of NK cell activity to the greatest extent is used as such a therapeutic or reagent.
  • Antisense nucleic acids may also be used to reduce the level of ICER activity in immune cells.
  • ICER antisense to various ICER isoforms has been stably transfected into several cell lines (18,24,25). It has been reported that select cell lines can be stably transfected with a construct which results in perpetual intracellular overexpression of ICER antisense, thereby blocking forskolin-inducible ICER synthesis in the transfected cells (18). Such cell lines do not experience lethality or apparent toxicity from stable ICER-antisense expression per se, but ICER-dependent effects of cAMP-stimulating agents or agonists are blocked.
  • normal human T cells can be stably transfected with vectors hyperexpressing ICER antisense to reduce or prevent the inhibitory effects of ICER induced by tumors and other pathogens. Because certain constructs block endogenous ICER induction in some cell lines (25) but not in others 55
  • antisense sequence(s) are screened to identify those that are efficient for reducing or preventing endogenous induction, and to determine whether each ICER isoform has different suppressibility by a particular antisense sequence.
  • ICER antisense nucleic acids which reduce cAMP-induced inhibition of the activity of immune cells, T lymphocytes, B lymphocytes, NK cells, monocytes, dendritic cells, and antigen presenting cells, are identified as follows.
  • ICER mRNA and ICER protein after exposure to the cAMP agonists forskolin and sustained ICER mRNA expression occurs after combined treatment with ionomycin plus forskolin.
  • Treatment of such T cells with cAMP-stimulating agents or agonists such as forskolin or PGE2 also results in marked prolonged blockade of T cell proliferation whether the proliferation is stimulated by calcium ionophore or by specific antigenic restimulation.
  • the ability of antisense nucleic acids to reduce ICER-mediated inhibition of T cell activity may be measured by determining their ability to block the inhibition of T cells treated with forskolin, PGE2 or ionomycin plus forskolin.
  • a set of nucleic acids complementary to all or a portion of one or more forms of ICER mRNA is prepared.
  • the antisense nucleic acids are oligonucleotides comprising less than 50 consecutive nucleotides complementary to one or more forms of ICER mRNA.
  • the antisense nucleic acids comprise at least 75 consecutive nucleotides complementary to one or more forms of ICER mRNA.
  • the antisense nucleic acids comprise at least 100 consecutive nucleotides complementary to one or more forms of ICER mRNA.
  • the antisense nucleic acids comprise at least 150 consecutive nucleotides complementary to one or more forms of ICER mRNA.
  • the antisense nucleic acids comprise at least 200 consecutive nucleotides complementary to one or more forms of ICER mRNA. In still further embodiments, the antisense nucleic acids comprise more than 200 consecutive nucleotides complementary to one or more forms of
  • the antisense nucleic acids comprise nucleic acids which are complementary to the total sequence of one or more forms of ICER mRNA.
  • the antisense nucleic acids may comprise oligonucleotide sequences which constitute
  • antisense to various portions of the ICER gene, including the initiation codon common to all four isoforms of ICER, the termination codon present in individual isoforms, or any other sequence present in one or more ICER isoforms.
  • oligonucleotides may be synthesized using conventional techniques.
  • an antisense sequence common to all isoforms of ICER which runs from the region approximately 60 oligonucleotides upstream to the initiation codon, continuing through the first translated 24 oligonucleotides in the ICER specific domain (-60 through +24 on the ICER sequence published in Figure 2 of Fujimoto et al. (26) is used. 56
  • the antisense sequence is longer than 50 bases in length, it may be synthesized by performing in vitro tranc ⁇ ption reactions on vectors in which a nucleic acid encoding the antisense sequence is operably linked to a promoter Alternatively, vectors encoding the antisense nucleic acid may be transiently or stably introduced into the T cells as described above.
  • the effect of each antisense nucleic acid on ICER activity in T cells may be evaluated using a variety of systems. In one assay, the effect of each antisense nucleic acid on ICER activity in T cells is determined by quantitating its ability to reduce or disrupt the forskolin induced inhibition of T cell proliferation.
  • T cells are prepulsed with the antisense nucleic acids to be screened, or with combinations of antisense nucleic acids prior to exposure to cAMP-stimulating agents or agonists such as forskolin.
  • Immunoprecipitation and/or RNAse protection assays are performed to identify those antisense oligonucleotide sequences which are capable of potently blocking forskolin induced ICER expression in these T cells.
  • the results obtained with each of the antisense nucleic aicds being screened are compared to those in cells which received control antisense nucleic acids.
  • Antisense nucleic acids which reduce ICER expression levels or mRNA levels to a statiscally significant extent may be used as therapeutics or as reagents for studying the molecular mechanisms which govern immune cell activity.
  • the antisense nucleic acid which reduces ICER expression to the greatest extent is used as such a therapeutic or reagent.
  • ICER antisense may also be used to reduce or prevent
  • each antisense nucleic acid on ICER activity in T cells is determined by quantitating its ability to reduce or disrupt cAMP-induced suppression of T cell function using standard assays for measuring T cell proliferation, cytokine release asays, signal transduction and target lysis assays and comparing the results to those obtained with control antisense nucleic acids.
  • Those antisense nucleic acids which reduce ICER expression levels or mRNA levels to a statiscally significant extent may be used as therapeutics or as reagents for studying the molecular mechanisms which govern immune cell activity.
  • the antisense nucleic acid which reduces ICER expression to the greatest extent is used as such a therapeutic or reagent.
  • vectors comprising nucleotide sequences encoding each of the test antisense nucleic acids operably linked to a promoter are introduced into T cells, such as freshly cultured CD4 * anti TETANUS T cells.
  • the vector may comprise any of the vectors conventionally used to express nucleic acids in immune cells, including retroviral vectors (28,29), episomal vectors, vectors which are stably integrated into the genome of the host cell, or vectors which are transiently present in the host cell.
  • retroviral vectors 28,29
  • episomal vectors vectors which are stably integrated into the genome of the host cell, or vectors which are transiently present in the host cell.
  • a vector encoding a sense nucleic acid or an antisense nucleic acid which targets an mRNA other than an ICER mRNA is introduced in the T cells.
  • Immunoprecipitation with ICER antibodies or RNAse protection assays is performed to measure the levels of ICER protein or intact ICER mRNA present in T cells containing vectors encoding each of the test antisense nucleic acids. The results are compared to the levels in T cells receiving control antisense nucleic acids.
  • Antisense nucleic acids which reduce ICER expression levels or mRNA levels to a statiscally significant extent may be used as therapeutics or 57 as reagents for studying the molecular mechanisms which govern immune cell activity.
  • the antisense nucleic acid which reduces ICER expression to the greatest extent is used as such a therapeutic or reagent.
  • the ability of the antisense nucleic acids to inhibit T cell activity in vivo is determined as follows. Test and control antisense nucleic acids are introduced into T cells using any of the above methods (i.e. naked nucleic acids, lipofection, and stable or transient expression vectors). The T cells are then administered to same-strain tumor bearing mice to measure the ability of the antisense nucleic acids to inhibit ICER-mediated inhibition of the immune response. The results obtained with each of the test antisense nucleic acids are compared to those obtained with the controls.
  • Antisense nucleic acids which reduce ICER-mediated inhibition of the immune response to a statiscally significant extent may be used as therapeutics or as reagents for studying the molecular mechanisms which govern immune cell activity.
  • the antisense nucleic acid which reduces ICER-mediated inhibition of the immune response to the greatest extent is used as such a therapeutic or reagent.
  • Antisense nucleic acids may also be used to reduce ICER-mediated inhibition of immune cell activity in immune cells other than T cells, such as B cells, NK cells, dendritic cells, or antigen presenting cells. Methods for identifying antisense nucleic acids which effectively reduce ICER-mediated inhibition of antigen presenting cell activity are described below.
  • Example 34 Identification of ICER Antisense Molecules which Reduce ICER-mediated Inhibition of Antigen Presenting Cell Activity
  • ICER antisense nucleic acids are screened for the ability to reduce or prevent ICER-mediated inhibition of antigen presenting cells, such as monocytes or dendritic cells using the procedures described above for T cells.
  • cAMP-stimulating agents or agonists such as PGE2 and forskolin have been shown to have a variety of inhibitory effects on antigen-presenting cells (APC), including inhibition of IL- 1 secretion and inhibited upregulation of the costimulatory molecule B7.1 (see above).
  • APC such as monocytes and dendritic cells (DC) are stimulated with cAMP stimulating agents and treated with the ICER antisense nucleic acids or antisense nucelic acids as described in the T cell assays above.
  • ICER-mediated inhibition may be measured by measuring the PGE2/forskoiin-induced inhibition of calcium-ionophore-stimulated CD80 (B7.1) expression in peripheral blood human monocytes (4).
  • Antisense nucleic acids which reduce the inhibition of antigen presenting cell activity to a statiscally significant extent may be used as therapeutics or as reagents for studying the molecular mechanisms which govern immune cell activity.
  • the antisense nucleic acid which reduces the inhibition of antigen presenting cell activity to the greatest extent is used as such a therapeutic or reagent.
  • ICER antisense nucleic acids to reduce or prevent the ICER-mediated inhibition of B lymphocyte activity may also be confirmed as follows.
  • ICER antisense nucleic acids and control nucleic acids are transiently or introduced into B lymphocytes treated with cAMP agonists as described above.
  • Antisense nucleic acids which reduce the inhibition of B cell activity to a statiscally significant extent may be used as therapeutics or as reagents for studying the molecular mechanisms which govern immune cell activity.
  • the antisense nucleic acid which reduces the inhibition of B cell activity to the greatest extent is used as such a therapeutic or reagent.
  • ICER antisense nucleic acids to reduce or prevent the ICER-mediated inhibition of NK cell activity may also be confirmed as follows.
  • ICER antisense nucleic acids and control nucleic acids are transiently or stably introduced into NK cells treated with cAMP agonists as described above.
  • the extent of inhibition of target directed lysis by NK cells by cAMP agonists is determined in NK cells receiving the ICER antisense nucleic acids and control nucleic acids.
  • Antisense nucleic acids which reduce the inhibition NK cell activity to a statiscally significant extent may be used as therapeutics or as reagents for studying the molecular mechanisms which govern immune cell activity.
  • the antisense nucleic acid which reduces the inhibition of NK cell activity to the greatest extent is used as such a therapeutic or reagent.
  • agents which reduce the levels of ICER activity in immune cells may be used as therapeutics to ameliorate or cure conditions which result from or which are exacerbated by ICER-mediated inhibition of immune cell activity.
  • agents which reduce the level of ICER activity in immune cells may be used to treat individuals suffering from cancer or infection with a pathogenic organism.
  • agents which increase the levels of ICER activity may be used as therapeutics to ameliorate or cure conditions which result from or which are exacerbated by an elevated level of immune cell activity.
  • Such conditions include arthritis and lupus
  • immune cells are obtained from an individual suffering from a condition to be treated.
  • the agent which reduces or increases the level of ICER activity in immune cells is introduced into the immune cells using any of the gene therapy techniques familiar to those skilled in the art.
  • the agent may be introduced using techniques for introducing naked nucleic acids into cells, lipofection techniques, transfection techniques, or using vectors encoding the agent which are transiently or stably maintained in the host cells.
  • the agent may be a ribozyme, an antisense nucleic acid, a composition which upregulates or downregulates the 59 transcription of the ICER gene, or a composition which modulates the level of ICER protein in immune cells. After the agent is introduced into the immune cells, the cells are reintroduced into the individual.
  • the agent is introduced into the immune cells while the immune cells are in the individual suffering from the condition to be treated.
  • the agent may be introduced as a naked nuceic acid, in a lipid vesicle, or via a vector encoding the agent which is stably or transiently maintained in the host cell.
  • the agent may be a ribozyme, an antisense nucleic acid, a composition which upregulates or downregulates the transcription of the ICER gene, or a composition which modulates the level of ICER protein in immune cells.
  • Example 38 describes the use of an ICER ribozyme or antisense nucleic acid to reduce ICER-mediated inhibtion of T cell activity in individuals suffering from cancer, infection with a pathogenic microorganism, or from any other condition resulting from or exacerbated by ICER-mediated inhibition of T cell activity.
  • T lymphocytes are isolated from subjects suffering from cancer, infection with a pathogenic microorganism, or from any other condition resulting from or exacerbated by ICER-mediated inhibition of T cell activity.
  • the T lymphocytes may be either CD4 + T cells, CD8 * T cells, or both, and may include subpopulations which possess anti- tumor specificity and function (for example, because the patient previously received a tumor vaccine to activate and increase the incidence of such subpopulations).
  • the T cells are propagated for several days or weeks in culture, driven by a variety of stimuli such as superantigens or autologous antigen-pulsed dendritic cells (DC), and by the addition of cytokines such as rhlL-2.
  • stimuli such as superantigens or autologous antigen-pulsed dendritic cells (DC), and by the addition of cytokines such as rhlL-2.
  • DC autologous antigen-pulsed dendritic cells
  • the T cells are transfected with retroviral vectors containing sequences which generate ICER antisense, ICER ribozymes, or other agents which reduce ICER activity when expressed in the transduced cells.
  • retroviral vectors containing sequences which generate ICER antisense, ICER ribozymes, or other agents which reduce ICER activity when expressed in the transduced cells.
  • Recent advances in transfection techniques permit successful gene transfer in up to 50% of the total lymphocyte population (28,29).
  • the lymphocytes are propagated to adequate numbers and stable gene transfer confirmed, the lymphocytes are administered to the subjects suffering from cancer as adoptive therapy.
  • the transduced lymphocytes are resistant to induction of sustained ICER protein synthesis in the tumor environment and thus possess markedly enhanced anti-tumor function.
  • a "suicide gene” such as the Herpes Simplex-thymidine kinase (HS-tk) gene may be cotransfected with the ICER antisense or ICER ribozyme vector.
  • the suicide gene allows HS-tk containing transduced T cells to be killed by treatment of the subject with ganciclovir (28).
  • Example 39 describes the use of ICER ribozymes or ICER antisense to reduce ICER-mediated inhibition of monocyte or dendritic cell activity in individuals suffering from cancer, infection with a pathogenic microorganism, or from any other condition resulting from or exacerbated by ICER-mediated inhibition of monocyte or dendritic cell activity.
  • Peripheral blood monocytes (themselves precursors of both macrophages and dendritic cells), or cultured myeloid precursors of monocytes, macrophages and DC (such as CD34 * bone marrow cells) are harvested from subjects suffering from cancer, infection with a pathogenic microorganism, or from any other condition resulting from or exacerbated by ICER-mediated inhibition of T cell activity, and briefly cultured to achieve stable transfection with retroviral vectors containing sequences which generate ICER antisense, ICER ribozymes, or other agents which reduce ICER activity when expressed in the transduced cells.
  • a "suicide gene” such as the Herpes Simplex-thymidine kinase (HS-tk) gene (28) may be cotransfected (see above).
  • the cells are readministered to the patients, providing a potentially self-sustaining precursor pool of antigen-presenting cells which are resistant to induction of sustained ICER protein synthesis in the tumor environment, thereby enhancing their potential for effective antigen presentation.
  • HS-tk Herpes Simplex-thymidine kinase
  • the above procedures may also be performed to introduce agents which reduce ICER-mediated inhibition into other types of immune cells, including B cells, NK cells, and antigen presenting cells, in subjects suffering from a condition resulting from or exacerbated by ICER-mediated inhbition of immune cell activity.
  • the above procedures may be used to treat conditions resulting from or exacerbated by elevated levels of immune cell activity.
  • a vector encoding one or more ICER isoforms or an agent which increases ICER acitivity is introduced into an individual suffering from such a condition as described above.
  • Agents which reduce or increase ICER activity may also be used as reagents to study the molecular mechanisms and pathways which govern immune cell activity. For example, many agents besides cAMP agonists inhibit cells of the immune system, including IL-10 and glucocorticoids (see above).
  • tumor cells and infectious pathogens may inhibit cells of the immune system through (1 ) production of putative inhibitory factors such as prostaglandins and IL- 10 (see above); (2) induction of putative inhibitory factors in host cells (see above); (3) production of currently unidentified factors; (4) induction of currently unidentified factors.
  • putative inhibitory factors such as prostaglandins and IL- 10
  • induction of putative inhibitory factors in host cells see above
  • production of currently unidentified factors production of currently unidentified factors
  • agents which reduce the activity of ICER may be introduced into immune cells and to determine whether they reduce or abrogate the ability of the above agents to inhibit immune cell activity.
  • agents which increase ICER activity may be introduced into immune cells and their ability to reduce or prevent further inhibition of immune cell activity may be measured.
  • in vitro or in vivo analyses such as those described above may be performed to determine whether the inhibitory effects of such agents as rlL-10, glucocorticoids, or tumor-derived materials on cells of the immune system, such as T cells, B cells, NK cells, and APCs are also blocked by ICER antisense nucleic acids or ICER ribozymes.
  • Cells treated with rlL-10, glucocorticoids, or tumor derived materials are loaded wih ICER antisense nucleic acids or ribozymes or designed to stably express ICER antisense nucleic acids or ribozymes as described above.
  • the level of inhibition of immune cell activity is measured in cells receiving the agents and compared to that observed in cells receiving control nucleic acids to identify factors which inhibit immune cell activity via ICER.
  • RINSR Repressor(s) of ICER Negative Self-regulation
  • nucleic acids encoding the RINSR protein(s) are isolated as follows.
  • Example 40 Detection and Isolation of RINSR Standardized techniques such as Differential Display, Serial Analysis of Gene Expression (SAGE), and/or Gene CallingTM (Curagen Corp.) are used to identify mRNAs/proteins uniquely synthesized in response to combined stimuli (e.g., forskolin plus ionomycin) which result in sustained expression of ICER. mRNAs or proteins synthesized in response to such combined stimuli but not to either stimulus are likely to constitute factors responsible for repressing ICER negative self-regulation. The genes encoding such proteins are cloned using standard techniques and the protein and mRNA sequences are examined to determine whether they are identical to putative mRNAs/proteins, or whether they represent previously unidentified regulatory elements. Antisense intervention therapies in which RINSR antisense is used to block sustained RINSR expression are then designed.
  • SAGE Serial Analysis of Gene Expression
  • Gene CallingTM Gene CallingTM
  • ICER autoregulation may be inhibited by RINSR, a protein(s) which prevents ICER from inhibiting its own transcription.
  • RINSR a protein(s) which prevents ICER from inhibiting its own transcription.
  • cells such as T cells, B cells, NK cells, monocytes, dendritic cells, or other APCs are treated with cAMP agonists and either RINSR antisense or control sense nucleic acids as described above.
  • ICER-mediated inhibition of immune cell activity is reduced or prevented in cells receiving RINSR antisense but not in cells receiving control nucleic acids.
  • ICER antisense may be used to reduce or prevent ICER-mediated inhibition of immune cell activity in subjects in which immune cell activity is repressed by tumors or pathogenic agents. Representative examples of the use of ICER antisense as a therapeutic for reducing or preventing ICER-mediated inhibition of immune cell activity are described below. However, it will be appreciated that ICER antisense may be used as a therapeutic to treat any condition in which immune cell activity is inhibited by ICER.
  • strategies other than ICER antisense or ICER ribozymes may be employed to reduce or prevent ICER-mediated inhibition of immune cell activity.
  • Such strategies include any method of blocking or reducing transcription of the ICER gene, translation of the ICER mRNA, or the activity of the ICER protein.
  • peptides which block or reduce the activity of ICER or RINSR may be employed.
  • Penix LA. Sweetser M.T., Weaver W.M., Hoeffler J.P., Kerppola T.K., and Wilson C.B. (1996) 1 B io I Ch e m 271, 31964-31972 52. Hodge M.R., Rooney J.W., and Glimcher L.H. (1995) 11 m m u n o 1 154, 6397-405

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des réactifs et des méthodes de modulation de l'activité de cellules immunitaires à l'aide d'agents régulant l'activité de ICER.
EP99903134A 1998-02-27 1999-01-15 Blocage therapeutique de la synthese de icer pour prevenir l'inhibition a mediation icer de l'activite de cellules immunitaires Withdrawn EP1056843A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7629398P 1998-02-27 1998-02-27
US76293P 1998-02-27
PCT/US1999/000967 WO1999043814A1 (fr) 1998-02-27 1999-01-15 Blocage therapeutique de la synthese de icer pour prevenir l'inhibition a mediation icer de l'activite de cellules immunitaires

Publications (1)

Publication Number Publication Date
EP1056843A1 true EP1056843A1 (fr) 2000-12-06

Family

ID=22131078

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99903134A Withdrawn EP1056843A1 (fr) 1998-02-27 1999-01-15 Blocage therapeutique de la synthese de icer pour prevenir l'inhibition a mediation icer de l'activite de cellules immunitaires

Country Status (5)

Country Link
EP (1) EP1056843A1 (fr)
JP (1) JP2002509861A (fr)
AU (1) AU2322799A (fr)
CA (1) CA2321993A1 (fr)
WO (1) WO1999043814A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060269524A1 (en) * 2004-02-19 2006-11-30 Kibun Food Chemifa Co., Ltd. Composition for nkt cell activation
CN112961827B (zh) * 2021-04-25 2024-04-26 河南省肿瘤医院 佛司可林在t细胞培养中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9943814A1 *

Also Published As

Publication number Publication date
JP2002509861A (ja) 2002-04-02
CA2321993A1 (fr) 1999-09-02
AU2322799A (en) 1999-09-15
WO1999043814A1 (fr) 1999-09-02

Similar Documents

Publication Publication Date Title
Lohoff et al. Roles of interferon-regulatory factors in T-helper-cell differentiation
Song et al. Transcriptional regulation of RANTES expression in T lymphocytes
Zhu et al. Functional association of Nmi with Stat5 and Stat1 in IL-2-and IFN γ-mediated signaling
Yang et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ
Mahone et al. Localized Bicaudal‐C RNA encodes a protein containing a KH domain, the RNA binding motif of FMR1.
Gong et al. Cytokine-dependent Blimp-1 expression in activated T cells inhibits IL-2 production
Dinarello IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family
Geiman et al. Lsh, an SNF2/helicase family member, is required for proliferation of mature T lymphocytes
Bodor et al. Suppression of T-cell responsiveness by inducible cAMP early repressor (ICER)
Lee et al. Differential regulation of constitutive major histocompatibility complex class I expression in T and B lymphocytes
US20050025751A1 (en) Modulators of Notch signalling for use in immunotherapy
Bamezai Mouse Ly-6 proteins and their extended family: markers of cell differentiation and regulators of cell signaling
US5958403A (en) Methods and compounds for prevention of graft rejection
Shashkova et al. Osteoclast-primed Foxp3+ CD8 T cells induce T-bet, eomesodermin, and IFN-γ to regulate bone resorption
US20120159661A1 (en) T-Bet Compositions and Methods of Use Thereof
Möröy The zinc finger transcription factor Growth factor independence 1 (Gfi1)
Miah et al. E gr2 induced during DC development acts as an intrinsic negative regulator of DC immunogenicity
Yan et al. Involvement of multiple transcription factors in regulation of IL-β-induced MCP-1 expression in alveolar type II epithelial cells
JP2000510333A (ja) 因子活性を調節することによりｔ細胞サブセットを制御するための方法及び組成物
Oki et al. Stat6 activation and Th2 cell proliferation driven by CD28 signals
Bodor et al. Differential inducibility of the transcriptional repressor ICER and its role in modulation of Fas ligand expression in T and NK lymphocytes
WO1999043814A1 (fr) Blocage therapeutique de la synthese de icer pour prevenir l'inhibition a mediation icer de l'activite de cellules immunitaires
Ho et al. Tissue-specific regulation of cytokine gene expression
Saiki et al. EMMPRIN inhibits bFGF-induced IL-6 secretion in an osteoblastic cell line, MC3T3-E1
JP2005511056A (ja) Ｔ−ｂｅｔ組成物およびそれらの使用方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000907

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010504

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021016